[{"filename": "bridgebio-pharma-unit-signs-multi-billion-dollar-deal-with-helsinn.json", "title": "BridgeBio Pharma unit signs multi-billion-dollar deal with Helsinn", "description": "BridgeBio Pharma unit signs multi-billion-dollar deal with Helsinn", "link": "https://www.thepharmaletter.com/article/bridgebio-pharma-unit-signs-multi-billion-dollar-deal-with-helsinn", "pubDate": "2021-03-31 16:45:00"}, {"filename": "latest-pfizer-biontech-results-offer-youthful-optimism.json", "title": "Latest Pfizer-BioNTech results offer youthful optimism", "description": "There was further encouraging news on the vaccine front on Wednesday as Pfizer and BioNTech announced positive findings on their vaccine from a Phase III trial ", "link": "https://www.thepharmaletter.com/article/latest-pfizer-biontech-results-offer-youthful-optimism", "pubDate": "2021-03-31 16:43:00"}, {"filename": "amzell-signs-agreement-with-amring-pharmaceuticals.json", "title": "Amzell signs agreement with Amring Pharmaceuticals", "description": "Amzell signs agreement with Amring Pharmaceuticals", "link": "https://www.thepharmaletter.com/article/amzell-signs-agreement-with-amring-pharmaceuticals", "pubDate": "2021-03-31 16:15:00"}, {"filename": "europe-s-legal-cannabis-market-predicted-to-reach-high-of-3-2-billion-euros-by-2025.json", "title": "Europe\u00e2\u0080\u0099s legal cannabis market predicted to reach high of 3.2 billion euros by 2025", "description": "The European cannabis market is forecast to grow with a compound annual growth rate (CAGR) of 67.4% to reach 3.2 billion euros ($3.75 billion) by 2025, a new re", "link": "https://www.thepharmaletter.com/article/europe-s-legal-cannabis-market-predicted-to-reach-high-of-3-2-billion-euros-by-2025", "pubDate": "2021-03-31 15:56:00"}, {"filename": "daiichi-sankyo-drops-out-of-vaccine-alliance-with-sanofi-in-japan.json", "title": "Daiichi Sankyo drops out of vaccine alliance with Sanofi in Japan", "description": "Daiichi Sankyo drops out of vaccine alliance with Sanofi in Japan", "link": "https://www.thepharmaletter.com/article/daiichi-sankyo-drops-out-of-vaccine-alliance-with-sanofi-in-japan", "pubDate": "2021-03-31 15:39:00"}, {"filename": "fda-accepts-abbvie-s-filing-for-atogepant-for-migraine-prevention.json", "title": "FDA accepts AbbVie's filing for atogepant for migraine prevention", "description": "FDA accepts AbbVie's filing for atogepant for migraine prevention", "link": "https://www.thepharmaletter.com/article/fda-accepts-abbvie-s-filing-for-atogepant-for-migraine-prevention", "pubDate": "2021-03-31 15:03:00"}, {"filename": "ec-approves-cabometyx-in-combination-with-opdivo.json", "title": "EC approves Cabometyx in combination with Opdivo", "description": "EC approves Cabometyx in combination with Opdivo", "link": "https://www.thepharmaletter.com/article/ec-approves-cabometyx-in-combination-with-opdivo", "pubDate": "2021-03-31 14:15:00"}, {"filename": "astellas-puts-gene-therapy-at-heart-of-r-d-strategy.json", "title": "Astellas puts gene therapy at heart of R&D strategy", "description": "Japanese company Astellas has become the latest drugmaker to make genetic regulation one of the primary focuses of its research and development (R&D) strategy.", "link": "https://www.thepharmaletter.com/article/astellas-puts-gene-therapy-at-heart-of-r-d-strategy", "pubDate": "2021-03-31 13:20:00"}, {"filename": "nda-group-s-figures-on-usa-and-eu-reflect-record-year-for-new-drug-approvals-despite-pandemic.json", "title": "NDA Group\u00e2\u0080\u0099s figures on USA and EU reflect record year for new drug approvals - despite pandemic", "description": NaN, "link": "https://www.thepharmaletter.com/article/nda-group-s-figures-on-usa-and-eu-reflect-record-year-for-new-drug-approvals-despite-pandemic", "pubDate": "2021-03-31 12:41:00"}, {"filename": "amgen-bags-15-pgdh-as-it-rides-in-with-a-bid-for-rodeo-therapeutics.json", "title": "Amgen bags 15-PGDH as it rides in with a bid for Rodeo Therapeutics", "description": "Amgen bags 15-PGDH as it rides in with a bid for Rodeo Therapeutics", "link": "https://www.thepharmaletter.com/article/amgen-bags-15-pgdh-as-it-rides-in-with-a-bid-for-rodeo-therapeutics", "pubDate": "2021-03-31 12:08:00"}, {"filename": "back-and-forth-on-astrazeneca-vaccine-adds-to-uncertainty.json", "title": "\"Back and forth\" on AstraZeneca vaccine adds to uncertainty", "description": "Germany has again updated its guidance on the use of Vaxzevria, after new reports related to a rare kind of blood clotting occurring in people who had previousl", "link": "https://www.thepharmaletter.com/article/back-and-forth-on-astrazeneca-vaccine-adds-to-uncertainty", "pubDate": "2021-03-31 11:41:00"}, {"filename": "conditional-ec-approval-for-karyopharm-s-nexpovio.json", "title": "Conditional EC approval for Karyopharm\u00e2\u0080\u0099s Nexpovio", "description": "Conditional EC approval for Karyopharm\u00e2\u0080\u0099s Nexpovio", "link": "https://www.thepharmaletter.com/article/conditional-ec-approval-for-karyopharm-s-nexpovio", "pubDate": "2021-03-31 11:19:00"}, {"filename": "stada-strengthens-oncology-offering-by-launching-oyavas-biosimilar.json", "title": "STADA strengthens oncology offering by launching Oyavas biosimilar", "description": "STADA strengthens oncology offering by launching Oyavas biosimilar", "link": "https://www.thepharmaletter.com/article/stada-strengthens-oncology-offering-by-launching-oyavas-biosimilar", "pubDate": "2021-03-31 10:14:00"}, {"filename": "new-report-views-progress-on-biosimilar-medicine-policies-across-europe.json", "title": "New report views progress on biosimilar medicine policies across Europe", "description": "New report views progress on biosimilar medicine policies across Europe", "link": "https://www.thepharmaletter.com/article/new-report-views-progress-on-biosimilar-medicine-policies-across-europe", "pubDate": "2021-03-31 10:13:00"}, {"filename": "pyxis-oncology-ends-busy-month-152-million-richer.json", "title": "Pyxis Oncology ends busy month $152 million richer", "description": "Just two weeks after announcing a worldwide licensing agreement with Pfizer to develop and commercialize multiple antibody drug conjugates (ADCs), Pyxis Oncolog", "link": "https://www.thepharmaletter.com/article/pyxis-oncology-ends-busy-month-152-million-richer", "pubDate": "2021-03-30 17:22:00"}, {"filename": "kazia-out-licenses-lead-product-in-greater-china.json", "title": "Kazia out-licenses lead product in Greater China", "description": "Kazia out-licenses lead product in Greater China", "link": "https://www.thepharmaletter.com/article/kazia-out-licenses-lead-product-in-greater-china", "pubDate": "2021-03-30 16:10:00"}, {"filename": "omega-in-126-million-series-c-financing.json", "title": "Omega in $126 million Series C financing", "description": "Privately-held US biotech Omega Therapeutics has closed an upsized Series C financing of $126 million.", "link": "https://www.thepharmaletter.com/article/omega-in-126-million-series-c-financing", "pubDate": "2021-03-30 15:53:00"}, {"filename": "setback-for-merck-which-gets-crl-for-keytruda-sbla.json", "title": "Setback for Merck, which gets CRL for Keytruda sBLA", "description": "Setback for Merck, which gets CRL for Keytruda sBLA", "link": "https://www.thepharmaletter.com/article/setback-for-merck-which-gets-crl-for-keytruda-sbla", "pubDate": "2021-03-30 14:11:00"}, {"filename": "roche-s-evrysdi-approved-in-europe-to-ramp-up-sma-rivalry.json", "title": "Roche\u00e2\u0080\u0099s Evrysdi approved in Europe to ramp up SMA rivalry", "description": "Swiss pharma giant Roche has seen its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) follow up its US approval by getting the green light from the Europ", "link": "https://www.thepharmaletter.com/article/roche-s-evrysdi-approved-in-europe-to-ramp-up-sma-rivalry", "pubDate": "2021-03-30 13:46:00"}, {"filename": "self-injectable-antibody-wins-multiple-sclerosis-nod-in-europe.json", "title": "Self-injectable antibody wins multiple sclerosis nod in Europe", "description": "Danish cancer specialist Genmab has announced the granting of European approval to its development partner, Novartis, for Kesimpta (ofatumumab).", "link": "https://www.thepharmaletter.com/article/self-injectable-antibody-wins-multiple-sclerosis-nod-in-europe", "pubDate": "2021-03-30 13:00:00"}, {"filename": "new-treatment-for-rare-bile-duct-cancer-in-europe.json", "title": "New treatment for rare bile duct cancer in Europe", "description": "Incyte has won European approval for Pemazyre (pemigatinib), as a second-line option for certain people with locally advanced or metastatic bile duct cancer.", "link": "https://www.thepharmaletter.com/article/new-treatment-for-rare-bile-duct-cancer-in-europe", "pubDate": "2021-03-30 12:15:00"}, {"filename": "global-drugmakers-again-demand-better-protection-of-patent-rights-in-russia.json", "title": "Global drugmakers again demand better protection of patent rights in Russia", "description": "Global drugmakers again demand better protection of patent rights in Russia", "link": "https://www.thepharmaletter.com/article/global-drugmakers-again-demand-better-protection-of-patent-rights-in-russia", "pubDate": "2021-03-30 12:03:00"}, {"filename": "novartis-oncology-expands-radioligand-pipeline-with-exclusive-worldwide-rights.json", "title": "Novartis Oncology expands radioligand pipeline with exclusive worldwide rights", "description": "Novartis Oncology expands radioligand pipeline with exclusive worldwide rights", "link": "https://www.thepharmaletter.com/article/novartis-oncology-expands-radioligand-pipeline-with-exclusive-worldwide-rights", "pubDate": "2021-03-30 11:11:00"}, {"filename": "gsk-rides-to-rescue-as-uk-eyes-neighbors-nervously.json", "title": "GSK rides to rescue as UK eyes neighbors nervously", "description": "British drugmaker GlaxoSmithKline has agreed to provide fill and finish services for Novavax\u00e2\u0080\u0099s (Nasdaq: NVAX) coronavirus vaccine, supplying 60 million doses fo", "link": "https://www.thepharmaletter.com/article/gsk-rides-to-rescue-as-uk-eyes-neighbors-nervously", "pubDate": "2021-03-30 10:35:00"}, {"filename": "call-for-cl-and-cheaper-tb-drugs-grows-louder-in-india.json", "title": "Call for CL and cheaper TB drugs grows louder in India", "description": "Call for CL and cheaper TB drugs grows louder in India", "link": "https://www.thepharmaletter.com/article/call-for-cl-and-cheaper-tb-drugs-grows-louder-in-india", "pubDate": "2021-03-30 10:28:00"}, {"filename": "uk-biotech-set-for-another-year-of-record-breaking-investment.json", "title": "UK biotech set for another year of record-breaking investment", "description": "UK biotech set for another year of record-breaking investment", "link": "https://www.thepharmaletter.com/article/uk-biotech-set-for-another-year-of-record-breaking-investment", "pubDate": "2021-03-30 10:27:00"}, {"filename": "germany-s-stada-arz-plans-to-accelerate-expansion-in-russian.json", "title": "Germany\u00e2\u0080\u0099s STADA Arz plans to accelerate expansion in Russian", "description": "Germany\u00e2\u0080\u0099s STADA Arz plans to accelerate expansion in Russian", "link": "https://www.thepharmaletter.com/article/germany-s-stada-arz-plans-to-accelerate-expansion-in-russian", "pubDate": "2021-03-30 10:20:00"}, {"filename": "indian-government-directed-by-court-to-notify-health-policy-for-rare-diseases.json", "title": "Indian government directed by Court to notify health policy for rare diseases", "description": "Indian government directed by Court to notify health policy for rare diseases", "link": "https://www.thepharmaletter.com/article/indian-government-directed-by-court-to-notify-health-policy-for-rare-diseases", "pubDate": "2021-03-29 16:13:00"}, {"filename": "samsung-bioepis-continues-roll-out-of-biosimilar-hadlima.json", "title": "Samsung Bioepis continues roll out of biosimilar Hadlima", "description": "Samsung Bioepis continues roll out of biosimilar Hadlima", "link": "https://www.thepharmaletter.com/article/samsung-bioepis-continues-roll-out-of-biosimilar-hadlima", "pubDate": "2021-03-29 15:52:00"}, {"filename": "fotivda-added-into-nccn-clinical-practice-guidelines.json", "title": "Fotivda added into NCCN clinical practice guidelines", "description": "The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include AVEO Oncology\u00e2\u0080\u0099s Fotivda (tivozanib) as a recommended re", "link": "https://www.thepharmaletter.com/article/fotivda-added-into-nccn-clinical-practice-guidelines", "pubDate": "2021-03-29 15:36:00"}, {"filename": "bms-latest-opdivo-submission-validated-by-ema.json", "title": "BMS\u00e2\u0080\u0099 latest Opdivo submission validated by EMA", "description": NaN, "link": "https://www.thepharmaletter.com/article/bms-latest-opdivo-submission-validated-by-ema", "pubDate": "2021-03-29 15:01:00"}, {"filename": "new-uniqure-findings-likely-to-diffuse-hemophilia-b-gene-therapy-scare.json", "title": "New uniQure findings likely to diffuse hemophilia B gene therapy scare", "description": "New uniQure findings likely to diffuse hemophilia B gene therapy scare", "link": "https://www.thepharmaletter.com/article/new-uniqure-findings-likely-to-diffuse-hemophilia-b-gene-therapy-scare", "pubDate": "2021-03-29 14:51:00"}, {"filename": "advances-in-pharmacological-treatment-for-amyloidosis.json", "title": "Advances in pharmacological treatment for amyloidosis", "description": "Advances in pharmacological treatment for amyloidosis", "link": "https://www.thepharmaletter.com/article/advances-in-pharmacological-treatment-for-amyloidosis", "pubDate": "2021-03-29 12:07:00"}, {"filename": "destiny-soars-on-new-data-for-xf-73-nasal-gel.json", "title": "Destiny soars on new data for XF-73 Nasal Gel", "description": "Destiny soars on new data for XF-73 Nasal Gel", "link": "https://www.thepharmaletter.com/article/destiny-soars-on-new-data-for-xf-73-nasal-gel", "pubDate": "2021-03-29 10:55:00"}, {"filename": "european-pharma-body-calls-for-commitment-to-hta-reforms.json", "title": "European pharma body calls for commitment to HTA reforms", "description": "A statement from the European pharma industry criticizes progress on a new proposal for making health technology assessments more efficient in the region.", "link": "https://www.thepharmaletter.com/article/european-pharma-body-calls-for-commitment-to-hta-reforms", "pubDate": "2021-03-29 10:21:00"}, {"filename": "fda-approves-first-car-t-therapy-for-multiple-myeloma.json", "title": "FDA approves first CAR-T therapy for multiple myeloma", "description": "FDA approves first CAR-T therapy for multiple myeloma", "link": "https://www.thepharmaletter.com/article/fda-approves-first-car-t-therapy-for-multiple-myeloma", "pubDate": "2021-03-29 10:13:00"}, {"filename": "fiocruz-scientists-detects-novel-alterations-in-the-sars-cov-2-spike-protein-in-brazil.json", "title": "Fiocruz scientists detects novel alterations in the Sars-CoV-2 Spike protein in Brazil", "description": "Fiocruz scientists detects novel alterations in the Sars-CoV-2 Spike protein in Brazil", "link": "https://www.thepharmaletter.com/article/fiocruz-scientists-detects-novel-alterations-in-the-sars-cov-2-spike-protein-in-brazil", "pubDate": "2021-03-29 10:10:00"}, {"filename": "look-back-at-pharma-news-in-the-week-to-march-26-2021.json", "title": "Look back at pharma news in the week to March 26, 2021", "description": "Look back at pharma news in the week to March 26, 2021", "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-march-26-2021", "pubDate": "2021-03-28 13:37:00"}, {"filename": "gsk-and-vir-file-eua-request-for-vir-7831-for-early-treatment-of-covid-19.json", "title": "GSK and Vir file EUA request for VIR-7831 for early treatment of COVID-19", "description": "GSK and Vir file EUA request for VIR-7831 for early treatment of COVID-19", "link": "https://www.thepharmaletter.com/article/gsk-and-vir-file-eua-request-for-vir-7831-for-early-treatment-of-covid-19", "pubDate": "2021-03-27 15:48:00"}, {"filename": "march-ema-chmp-meeting-sees-five-positive-novel-drugs-recommended.json", "title": "March EMA/CHMP meeting sees five positive novel drugs recommended", "description": "March EMA/CHMP meeting sees five positive novel drugs recommended", "link": "https://www.thepharmaletter.com/article/march-ema-chmp-meeting-sees-five-positive-novel-drugs-recommended", "pubDate": "2021-03-27 14:23:00"}, {"filename": "ema-chmp-six-recommendations-on-extensions-of-indications.json", "title": "EMA/CHMP: six recommendations on extensions of indications", "description": "EMA/CHMP: six recommendations on extensions of indications", "link": "https://www.thepharmaletter.com/article/ema-chmp-six-recommendations-on-extensions-of-indications", "pubDate": "2021-03-27 13:06:00"}, {"filename": "data-offer-further-evidence-on-akili-s-digital-therapeutic-in-adhd.json", "title": "Data offer further evidence on Akili\u00e2\u0080\u0099s digital therapeutic in ADHD", "description": NaN, "link": "https://www.thepharmaletter.com/article/data-offer-further-evidence-on-akili-s-digital-therapeutic-in-adhd", "pubDate": "2021-03-26 16:49:00"}, {"filename": "japan-s-mhlw-approves-a-new-car-t-cell-therapy-breyanzi.json", "title": "Japan\u00e2\u0080\u0099s MHLW approves a new CAR-T cell therapy, Breyanzi", "description": "Japan\u00e2\u0080\u0099s MHLW approves a new CAR-T cell therapy, Breyanzi", "link": "https://www.thepharmaletter.com/article/japan-s-mhlw-approves-a-new-car-t-cell-therapy-breyanzi", "pubDate": "2021-03-26 15:14:00"}, {"filename": "takeda-initiates-filing-for-dengue-vaccine-candidate-in-eu-and-endemic-countries.json", "title": "Takeda initiates filing for dengue vaccine candidate in EU and endemic countries", "description": "Takeda initiates filing for dengue vaccine candidate in EU and endemic countries", "link": "https://www.thepharmaletter.com/article/takeda-initiates-filing-for-dengue-vaccine-candidate-in-eu-and-endemic-countries", "pubDate": "2021-03-26 14:52:00"}, {"filename": "ema-s-chmp-at-last-backs-approving-covid-19-vaccines-production-plants.json", "title": "EMA\u00e2\u0080\u0099s CHMP at last backs approving COVID-19 vaccines production plants", "description": "EMA\u00e2\u0080\u0099s CHMP at last backs approving COVID-19 vaccines production plants", "link": "https://www.thepharmaletter.com/article/ema-s-chmp-at-last-backs-approving-covid-19-vaccines-production-plants", "pubDate": "2021-03-26 14:32:00"}, {"filename": "myrbetriq-approved-in-bladder-condition-affecting-children.json", "title": "Myrbetriq approved in bladder condition affecting children", "description": "A new US indication has been approved for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspensio", "link": "https://www.thepharmaletter.com/article/myrbetriq-approved-in-bladder-condition-affecting-children", "pubDate": "2021-03-26 14:05:00"}, {"filename": "usa-drops-lilly-s-biologic-monotherapy-for-covid-19.json", "title": "USA drops Lilly's biologic monotherapy for COVID-19", "description": "The USA has stopped distributing the antibody bamlanivimab as monotherapy to treat certain patients with COVID-19.", "link": "https://www.thepharmaletter.com/article/usa-drops-lilly-s-biologic-monotherapy-for-covid-19", "pubDate": "2021-03-26 13:19:00"}, {"filename": "fda-joint-adcom-returns-negative-vote-on-tanezumab-for-osteo-pain.json", "title": "FDA joint adcom returns negative vote on tanezumab for osteo pain", "description": "FDA joint adcom returns negative vote on tanezumab for osteo pain", "link": "https://www.thepharmaletter.com/article/fda-joint-adcom-returns-negative-vote-on-tanezumab-for-osteo-pain", "pubDate": "2021-03-26 12:00:00"}, {"filename": "syncona-cornerstones-148-million-series-c-financing-in-gyroscope.json", "title": "Syncona cornerstones $148 million Series C financing in Gyroscope", "description": "Syncona cornerstones $148 million Series C financing in Gyroscope", "link": "https://www.thepharmaletter.com/article/syncona-cornerstones-148-million-series-c-financing-in-gyroscope", "pubDate": "2021-03-26 11:04:00"}, {"filename": "ema-validates-gilead-s-trodelvy-maa-for-tn-breast-cancer.json", "title": "EMA validates Gilead\u00e2\u0080\u0099s Trodelvy MAA for TN breast cancer", "description": "EMA validates Gilead\u00e2\u0080\u0099s Trodelvy MAA for TN breast cancer", "link": "https://www.thepharmaletter.com/article/ema-validates-gilead-s-trodelvy-maa-for-tn-breast-cancer", "pubDate": "2021-03-26 10:36:00"}, {"filename": "europe-s-pharma-has-the-innovations-but-now-to-deliver-for-patients.json", "title": "Europe\u00e2\u0080\u0099s pharma has the innovations, but now to deliver for patients?", "description": "Europe\u00e2\u0080\u0099s pharma has the innovations, but now to deliver for patients?", "link": "https://www.thepharmaletter.com/article/europe-s-pharma-has-the-innovations-but-now-to-deliver-for-patients", "pubDate": "2021-03-26 10:06:00"}, {"filename": "trial-in-children-could-help-increase-vaccine-coverage.json", "title": "Trial in children could help increase vaccine coverage", "description": "Adding to existing trials in older children, Pfizer and BioNTech have initiated a study of their coronavirus vaccine in children aged 6-12.", "link": "https://www.thepharmaletter.com/article/trial-in-children-could-help-increase-vaccine-coverage", "pubDate": "2021-03-26 09:49:00"}, {"filename": "amzell-acquires-swiss-firm-bazell-pharma.json", "title": "Amzell acquires Swiss firm Bazell Pharma", "description": "Amzell acquires Swiss firm Bazell Pharma", "link": "https://www.thepharmaletter.com/article/amzell-acquires-swiss-firm-bazell-pharma", "pubDate": "2021-03-25 16:49:00"}, {"filename": "astrazeneca-and-j-j-face-viral-vector-shortages-for-covid-19-vaccines-says-analyst.json", "title": "AstraZeneca and J&J face viral vector shortages for COVID-19 vaccines, says analyst", "description": "AstraZeneca and J&J face viral vector shortages for COVID-19 vaccines, says analyst", "link": "https://www.thepharmaletter.com/article/astrazeneca-and-j-j-face-viral-vector-shortages-for-covid-19-vaccines-says-analyst", "pubDate": "2021-03-25 15:52:00"}, {"filename": "australian-approval-for-vertex-trikafta.json", "title": "Australian approval for Vertex\u00e2\u0080\u0099 Trikafta", "description": "Australian approval for Vertex\u00e2\u0080\u0099 Trikafta", "link": "https://www.thepharmaletter.com/article/australian-approval-for-vertex-trikafta", "pubDate": "2021-03-25 14:44:00"}, {"filename": "abpi-calls-for-ambitious-uk-cancer-strategy.json", "title": "ABPI calls for ambitious UK cancer strategy", "description": "The Association of the British Pharmaceutical Industry (ABPI) wants the UK government to make improving cancer outcomes a priority funding focus.", "link": "https://www.thepharmaletter.com/article/abpi-calls-for-ambitious-uk-cancer-strategy", "pubDate": "2021-03-25 12:46:00"}, {"filename": "basilea-provides-more-evidence-of-derazantinib-s-potential-in-icca.json", "title": "Basilea provides more evidence of derazantinib's potential in iCCA", "description": "Basilea provides more evidence of derazantinib's potential in iCCA", "link": "https://www.thepharmaletter.com/article/basilea-provides-more-evidence-of-derazantinib-s-potential-in-icca", "pubDate": "2021-03-25 12:20:00"}, {"filename": "uk-eu-talks-target-win-win-outcome-on-vaccine-supplies.json", "title": "UK-EU talks target \"win-win\" outcome on vaccine supplies", "description": "A joint statement from the UK Government and the European Union signals the latest attempt to draw a line under a long-running dispute over vaccine supplies in ", "link": "https://www.thepharmaletter.com/article/uk-eu-talks-target-win-win-outcome-on-vaccine-supplies", "pubDate": "2021-03-25 12:20:00"}, {"filename": "manufacturing-and-marketing-approval-in-japan-for-joyclu.json", "title": "Manufacturing and marketing approval in Japan for Joyclu", "description": "knee_arthritis_stock_credit_depositphotos", "link": "https://www.thepharmaletter.com/article/manufacturing-and-marketing-approval-in-japan-for-joyclu", "pubDate": "2021-03-25 11:34:00"}, {"filename": "india-delays-exports-of-astrazeneca-shot-italian-situation-explained.json", "title": "India delays exports of AstraZeneca shot; Italian situation explained", "description": "India delays exports of AstraZeneca shot; Italian situation explained", "link": "https://www.thepharmaletter.com/article/india-delays-exports-of-astrazeneca-shot-italian-situation-explained", "pubDate": "2021-03-25 10:27:00"}, {"filename": "more-positive-data-clarify-picture-on-astrazeneca-jab.json", "title": "More positive data clarify picture on AstraZeneca jab", "description": "Positive topline results from the primary analysis of AstraZeneca\u00e2\u0080\u0099s USA-based Phase III trial confirm the safety and efficacy of its coronavirus vaccine.", "link": "https://www.thepharmaletter.com/article/more-positive-data-clarify-picture-on-astrazeneca-jab", "pubDate": "2021-03-25 10:25:00"}, {"filename": "gsk-fires-moncef-slaoui-from-galvani-board.json", "title": "GSK fires Moncef Slaoui from Galvani board", "description": "GSK fires Moncef Slaoui from Galvani board", "link": "https://www.thepharmaletter.com/article/gsk-fires-moncef-slaoui-from-galvani-board", "pubDate": "2021-03-24 18:07:00"}, {"filename": "rna-therapy-shows-positive-trial-results-for-rare-blindness-disorders.json", "title": "RNA therapy shows positive trial results for rare blindness disorders", "description": "RNA therapy shows positive trial results for rare blindness disorders", "link": "https://www.thepharmaletter.com/article/rna-therapy-shows-positive-trial-results-for-rare-blindness-disorders", "pubDate": "2021-03-24 17:29:00"}, {"filename": "boehringer-says-it-did-well-in-2020-despite-impact-of-covid-19.json", "title": "Boehringer says it did well in 2020, despite impact of COVID-19", "description": "Boehringer says it did well in 2020, despite impact of COVID-19", "link": "https://www.thepharmaletter.com/article/boehringer-says-it-did-well-in-2020-despite-impact-of-covid-19", "pubDate": "2021-03-24 16:39:00"}, {"filename": "uae-investment-a-boost-for-uk-life-sciences.json", "title": "UAE investment a boost for UK life sciences", "description": "Abu Dhabi\u00e2\u0080\u0099s Mubadala Investment Company is to invest \u00c2\u00a3800 million ($1.1 billion), alongside \u00c2\u00a3200 million from the British government, in UK life sciences as par", "link": "https://www.thepharmaletter.com/article/uae-investment-a-boost-for-uk-life-sciences", "pubDate": "2021-03-24 15:48:00"}, {"filename": "two-in-house-drugs-expecting-approval-in-2021-says-tot-biopharm.json", "title": "Two in-house drugs expecting approval in 2021, says TOT Biopharm", "description": "Two in-house drugs expecting approval in 2021, says TOT Biopharm", "link": "https://www.thepharmaletter.com/article/two-in-house-drugs-expecting-approval-in-2021-says-tot-biopharm", "pubDate": "2021-03-24 15:32:00"}, {"filename": "fresenius-kabi-fined-50-million-by-doj-for-offenses-in-india.json", "title": "Fresenius Kabi fined $50 million by DoJ for offenses in India", "description": "Fresenius Kabi fined $50 million by DoJ for offenses in India", "link": "https://www.thepharmaletter.com/article/fresenius-kabi-fined-50-million-by-doj-for-offenses-in-india", "pubDate": "2021-03-24 14:04:00"}, {"filename": "deal-making-in-head-and-neck-cancer-to-start-yielding-dividends-for-patients.json", "title": "Deal-making in head and neck cancer to start yielding dividends for patients", "description": "A frenzy of deal-making activity in head and neck cancer is bringing late-stage clinical candidates into view, according to GlobalData.", "link": "https://www.thepharmaletter.com/article/deal-making-in-head-and-neck-cancer-to-start-yielding-dividends-for-patients", "pubDate": "2021-03-24 12:20:00"}, {"filename": "pfizer-takes-aim-at-coronavirus-and-vaccines-market.json", "title": "Pfizer takes aim at coronavirus and vaccines market", "description": "Pfizer, a leading developer of coronavirus vaccines, has made progress in a novel oral antiviral for the disease.", "link": "https://www.thepharmaletter.com/article/pfizer-takes-aim-at-coronavirus-and-vaccines-market", "pubDate": "2021-03-24 11:56:00"}, {"filename": "more-positive-data-for-semaglutide-in-weight-loss.json", "title": "More positive data for semaglutide in weight loss", "description": "More positive data for semaglutide in weight loss", "link": "https://www.thepharmaletter.com/article/more-positive-data-for-semaglutide-in-weight-loss", "pubDate": "2021-03-24 11:46:00"}, {"filename": "xoma-buys-future-milestones-and-royalties-from-viracta.json", "title": "XOMA buys future milestones and royalties from Viracta", "description": "XOMA buys future milestones and royalties from Viracta", "link": "https://www.thepharmaletter.com/article/xoma-buys-future-milestones-and-royalties-from-viracta", "pubDate": "2021-03-24 10:55:00"}, {"filename": "mabxience-expanding-biosimilar-and-cdmo-manufacturing-capacity.json", "title": "mAbxience expanding biosimilar and CDMO manufacturing capacity", "description": "mAbxience expanding biosimilar and CDMO manufacturing capacity", "link": "https://www.thepharmaletter.com/article/mabxience-expanding-biosimilar-and-cdmo-manufacturing-capacity", "pubDate": "2021-03-24 10:07:00"}, {"filename": "recordati-reports-positive-results-from-phase-iii-isturisa-trial-in-cushing-s-disease.json", "title": "Recordati reports positive results from Phase III Isturisa trial in Cushing\u00e2\u0080\u0099s disease", "description": "Family-owned Italian drugmaker Recordati has presented positive results from the Phase III LINC 4 study of Isturisa (osilodrostat) at the Endocrine Society\u00e2\u0080\u0099s An", "link": "https://www.thepharmaletter.com/article/recordati-reports-positive-results-from-phase-iii-isturisa-trial-in-cushing-s-disease", "pubDate": "2021-03-23 17:41:00"}, {"filename": "further-vindication-for-novartis-in-radioligand-space.json", "title": "Further vindication for Novartis in radioligand space", "description": "Swiss pharma giant Novartis has announced a positive result of its Phase III study with the radioligand therapy 177Lu-PSMA-617 in patients with advanced prostat", "link": "https://www.thepharmaletter.com/article/further-vindication-for-novartis-in-radioligand-space", "pubDate": "2021-03-23 17:14:00"}, {"filename": "chugai-gains-japanese-nod-for-polivy-as-lymphoma-therapy.json", "title": "Chugai gains Japanese nod for Polivy as lymphoma therapy", "description": "Chugai gains Japanese nod for Polivy as lymphoma therapy", "link": "https://www.thepharmaletter.com/article/chugai-gains-japanese-nod-for-polivy-as-lymphoma-therapy", "pubDate": "2021-03-23 16:57:00"}, {"filename": "taisho-files-for-japanese-approval-of-ozoralizumab.json", "title": "Taisho files for Japanese approval of ozoralizumab", "description": "Taisho files for Japanese approval of ozoralizumab", "link": "https://www.thepharmaletter.com/article/taisho-files-for-japanese-approval-of-ozoralizumab", "pubDate": "2021-03-23 16:06:00"}, {"filename": "roche-abandons-tominersen-program-in-manifest-huntington-s-disease.json", "title": "Roche abandons tominersen program in manifest Huntington\u00e2\u0080\u0099s disease", "description": "Roche abandons tominersen program in manifest Huntington\u00e2\u0080\u0099s disease", "link": "https://www.thepharmaletter.com/article/roche-abandons-tominersen-program-in-manifest-huntington-s-disease", "pubDate": "2021-03-23 15:00:00"}, {"filename": "fda-snubs-novo-nordisk-s-once-weekly-semaglutide.json", "title": "FDA snubs Novo Nordisk\u00e2\u0080\u0099s once-weekly semaglutide", "description": "FDA snubs Novo Nordisk\u00e2\u0080\u0099s once-weekly semaglutide", "link": "https://www.thepharmaletter.com/article/fda-snubs-novo-nordisk-s-once-weekly-semaglutide", "pubDate": "2021-03-23 14:17:00"}, {"filename": "us-regulator-approves-expanded-label-for-keytruda.json", "title": "US regulator approves expanded label for Keytruda", "description": "The US Food and Drug Administration has approved a label update for Merck & Co\u00e2\u0080\u0099s blockbuster checkpoint blocker, targeting advanced esophageal or gastroesophage", "link": "https://www.thepharmaletter.com/article/us-regulator-approves-expanded-label-for-keytruda", "pubDate": "2021-03-23 13:50:00"}, {"filename": "uk-government-outlines-ambition-to-put-research-at-heart-of-nhs.json", "title": "UK government outlines ambition to put research at heart of NHS", "description": "The UK government has set out its vision for the future of clinical research delivery.", "link": "https://www.thepharmaletter.com/article/uk-government-outlines-ambition-to-put-research-at-heart-of-nhs", "pubDate": "2021-03-23 13:45:00"}, {"filename": "amazon-threat-or-opportunity-for-pharmaceuticals.json", "title": "Amazon: threat or opportunity for pharmaceuticals?", "description": "Debbie Bowen-Heaton's, partner at Oliver Wight, provides an Expert View on\u00c2\u00a0how companies can prepare for the disruption Amazon's arrival in Europe's pharmaceuti", "link": "https://www.thepharmaletter.com/article/amazon-threat-or-opportunity-for-pharmaceuticals", "pubDate": "2021-03-23 13:39:00"}, {"filename": "teva-and-servier-spring-to-the-aid-of-russia-with-cancer-drugs.json", "title": "Teva and Servier spring to the aid of Russia with cancer drugs", "description": "Teva and Servier spring to the aid of Russia with cancer drugs", "link": "https://www.thepharmaletter.com/article/teva-and-servier-spring-to-the-aid-of-russia-with-cancer-drugs", "pubDate": "2021-03-23 12:04:00"}, {"filename": "cohbar-discoveries-a-shocker-to-scientists-says-ceo.json", "title": "CohBar discoveries \"a shocker to scientists\u00e2\u0080\u009d says CEO", "description": "Californian ageing specialist CohBar (Nasdaq: CWBR) is focused on treating mitochondrial diseases, but chief executive Steven Engle doesn\u00e2\u0080\u0099t rule out offering a ", "link": "https://www.thepharmaletter.com/article/cohbar-discoveries-a-shocker-to-scientists-says-ceo", "pubDate": "2021-03-23 11:46:00"}, {"filename": "russia-to-speed-registration-of-new-drugs-favoring-domestic-drugmakers.json", "title": "Russia to speed registration of new drugs; favoring domestic drugmakers", "description": "Russia to speed registration of new drugs; favoring domestic drugmakers", "link": "https://www.thepharmaletter.com/article/russia-to-speed-registration-of-new-drugs-favoring-domestic-drugmakers", "pubDate": "2021-03-23 11:29:00"}, {"filename": "marriage-of-private-equity-and-healthcare-has-a-bright-future-specialist-investor-says.json", "title": "Marriage of private equity and healthcare has a bright future, specialist investor says", "description": "There has never been a better time to raise money for companies in the life sciences sector, according to\u00c2\u00a0Ben\u00c2\u00a0Long, partner at UK-headquartered private equity f", "link": "https://www.thepharmaletter.com/article/marriage-of-private-equity-and-healthcare-has-a-bright-future-specialist-investor-says", "pubDate": "2021-03-23 11:09:00"}, {"filename": "positive-phase-iii-data-for-mycapssa.json", "title": "Positive Phase III data for Mycapssa", "description": "Positive Phase III data for Mycapssa", "link": "https://www.thepharmaletter.com/article/positive-phase-iii-data-for-mycapssa", "pubDate": "2021-03-23 10:53:00"}, {"filename": "roche-cocktail-stops-coronavirus-and-key-variants.json", "title": "Roche cocktail stops coronavirus and key variants", "description": "Topline data from a trial testing an antibody cocktail in non-hospitalized people with the novel coronavirus show a reduction in the risk of hospitalisation or ", "link": "https://www.thepharmaletter.com/article/roche-cocktail-stops-coronavirus-and-key-variants", "pubDate": "2021-03-23 10:18:00"}, {"filename": "excitement-and-skepticism-at-prospects-of-provention-bio-s-teplizumab.json", "title": "Excitement and skepticism at prospects of Provention Bio\u00e2\u0080\u0099s teplizumab", "description": "The odds for and against betting on Provention Bio\u00e2\u0080\u0099s teplizumab, which is being studied in the prevention of type 1 diabetes (T1D) among at-risk patients, have ", "link": "https://www.thepharmaletter.com/article/excitement-and-skepticism-at-prospects-of-provention-bio-s-teplizumab", "pubDate": "2021-03-22 17:47:00"}, {"filename": "new-data-shows-strength-in-vistagen-s-ph94b-for-sad.json", "title": "New data shows strength in VistaGen\u00e2\u0080\u0099s PH94B for SAD", "description": "New data shows strength in VistaGen\u00e2\u0080\u0099s PH94B for SAD", "link": "https://www.thepharmaletter.com/article/new-data-shows-strength-in-vistagen-s-ph94b-for-sad", "pubDate": "2021-03-22 17:01:00"}, {"filename": "ema-says-ivermectin-should-not-be-used-for-covid-19.json", "title": "EMA says ivermectin should not be used for COVID-19", "description": "EMA says ivermectin should not be used for COVID-19", "link": "https://www.thepharmaletter.com/article/ema-says-ivermectin-should-not-be-used-for-covid-19", "pubDate": "2021-03-22 14:22:00"}, {"filename": "sifi-s-turkish-offensive-taking-shape.json", "title": "SIFI's Turkish offensive taking shape", "description": "Italian oncology company SIFI has announced the granting of marketing authorization in Turkey of four of its products.", "link": "https://www.thepharmaletter.com/article/sifi-s-turkish-offensive-taking-shape", "pubDate": "2021-03-22 12:45:00"}, {"filename": "evgen-pharma-names-chief-business-officer.json", "title": "Evgen Pharma names chief business officer", "description": "Evgen Pharma names chief business officer", "link": "https://www.thepharmaletter.com/article/evgen-pharma-names-chief-business-officer", "pubDate": "2021-03-22 12:38:00"}, {"filename": "faron-pharma-leaps-on-new-data-for-clevegen.json", "title": "Faron Pharma leaps on new data for Clevegen", "description": "Faron Pharma leaps on new data for Clevegen", "link": "https://www.thepharmaletter.com/article/faron-pharma-leaps-on-new-data-for-clevegen", "pubDate": "2021-03-22 12:02:00"}, {"filename": "tecentriq-trial-hits-primary-endpoint-in-lung-cancer.json", "title": "Tecentriq trial hits primary endpoint in lung cancer", "description": "Roche has announced that the Phase III IMpower010 study of Tecentriq (atezolizumab) met its primary endpoint of disease-free survival (DFS) at the interim analy", "link": "https://www.thepharmaletter.com/article/tecentriq-trial-hits-primary-endpoint-in-lung-cancer", "pubDate": "2021-03-22 11:28:00"}, {"filename": "evotec-inks-another-drug-discovery-deal-with-takeda.json", "title": "Evotec inks another drug discovery deal with Takeda", "description": "Evotec inks another drug discovery deal with Takeda", "link": "https://www.thepharmaletter.com/article/evotec-inks-another-drug-discovery-deal-with-takeda", "pubDate": "2021-03-22 11:06:00"}, {"filename": "strong-data-clear-path-for-new-covid-19-vaccine-in-usa.json", "title": "Strong data clear path for new COVID-19 vaccine in USA", "description": "A long-awaited USA-based Phase III trial of Covid-19 Vaccine AstraZeneca has proved successful, paving the way for its use in the country.", "link": "https://www.thepharmaletter.com/article/strong-data-clear-path-for-new-covid-19-vaccine-in-usa", "pubDate": "2021-03-22 10:17:00"}, {"filename": "first-indigenous-covid-19-vaccine-from-fiocruz-registered-in-brazil.json", "title": "First indigenous COVID-19 vaccine, from Fiocruz, registered in Brazil", "description": "First indigenous COVID-19 vaccine, from Fiocruz, registered in Brazil", "link": "https://www.thepharmaletter.com/article/first-indigenous-covid-19-vaccine-from-fiocruz-registered-in-brazil", "pubDate": "2021-03-22 10:14:00"}, {"filename": "hungarian-patients-have-ever-better-chances-but-still-work-to-be-done-says-trade-group.json", "title": "Hungarian patients have ever better chances, but still work to be done, says trade group", "description": "Hungarian patients have ever better chances, but still work to be done, says trade group", "link": "https://www.thepharmaletter.com/article/hungarian-patients-have-ever-better-chances-but-still-work-to-be-done-says-trade-group", "pubDate": "2021-03-22 10:13:00"}, {"filename": "look-back-at-pharma-news-in-the-week-to-march-19-2021.json", "title": "Look back at pharma news in the week to March 19, 2021", "description": "Look back at pharma news in the week to March 19, 2021", "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-march-19-2021", "pubDate": "2021-03-21 11:25:00"}, {"filename": "clovis-oncology-soars-as-rubraca-scores-in-ovarian-cancer-trial.json", "title": "Clovis Oncology soars as Rubraca scores in ovarian cancer trial", "description": "Clovis Oncology soars as Rubraca scores in ovarian cancer trial", "link": "https://www.thepharmaletter.com/article/clovis-oncology-soars-as-rubraca-scores-in-ovarian-cancer-trial", "pubDate": "2021-03-20 15:08:00"}, {"filename": "biden-nominee-for-head-of-hhs-gets-senate-backing-just.json", "title": "Biden nominee for head of HHS gets Senate backing, just", "description": "Biden nominee for head of HHS gets Senate backing, just", "link": "https://www.thepharmaletter.com/article/biden-nominee-for-head-of-hhs-gets-senate-backing-just", "pubDate": "2021-03-19 17:24:00"}, {"filename": "weekly-hgh-jabs-rushing-to-china.json", "title": "Weekly HGH jabs rushing to China", "description": "Weekly HGH jabs rushing to China", "link": "https://www.thepharmaletter.com/article/weekly-hgh-jabs-rushing-to-china", "pubDate": "2021-03-19 16:07:00"}, {"filename": "janssen-s-ponvory-approved-after-beating-competitor-in-trial.json", "title": "Janssen\u00e2\u0080\u0099s Ponvory approved after beating competitor in trial", "description": "The US Food and Drug Administration (FDA) has approved Ponvory (ponesimod).a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator.to tr", "link": "https://www.thepharmaletter.com/article/janssen-s-ponvory-approved-after-beating-competitor-in-trial", "pubDate": "2021-03-19 14:49:00"}, {"filename": "sanofi-gives-notice-it-is-termination-deal-with-oxford-biomedica.json", "title": "Sanofi gives notice it is termination deal with Oxford Biomedica", "description": "Sanofi gives notice it is termination deal with Oxford Biomedica", "link": "https://www.thepharmaletter.com/article/sanofi-gives-notice-it-is-termination-deal-with-oxford-biomedica", "pubDate": "2021-03-19 14:21:00"}, {"filename": "pivotal-failure-dents-promise-of-checkpoint-blocker-complement.json", "title": "Pivotal failure dents promise of checkpoint blocker complement", "description": "USA-based oncology specialist Idera Pharmaceuticals (Nasdaq: IDRA) has been dealt a severe blow by a negative result from the pivotal ILLUMINATE-301 trial.", "link": "https://www.thepharmaletter.com/article/pivotal-failure-dents-promise-of-checkpoint-blocker-complement", "pubDate": "2021-03-19 14:08:00"}, {"filename": "fda-approves-first-treatment-for-recurrent-pericarditis.json", "title": "FDA approves first treatment for recurrent pericarditis", "description": "FDA approves first treatment for recurrent pericarditis", "link": "https://www.thepharmaletter.com/article/fda-approves-first-treatment-for-recurrent-pericarditis", "pubDate": "2021-03-19 12:39:00"}, {"filename": "russia-s-rdif-partners-with-stelis-to-supply-200-million-doses-of-the-sputnik-v-vaccine.json", "title": "Russia\u00e2\u0080\u0099s RDIF partners with Stelis to supply 200 million doses of the Sputnik V vaccine", "description": "Russia\u00e2\u0080\u0099s RDIF partners with Stelis to supply 200 million doses of the Sputnik V vaccine", "link": "https://www.thepharmaletter.com/article/russia-s-rdif-partners-with-stelis-to-supply-200-million-doses-of-the-sputnik-v-vaccine", "pubDate": "2021-03-19 11:59:00"}, {"filename": "incyte-says-phase-iii-jakafi-trial-misses-endpoint-for-covid-1-associated-ards.json", "title": "Incyte says Phase III Jakafi trial misses endpoint for COVID-1-associated ARDS", "description": "Incyte says Phase III Jakafi trial misses endpoint for COVID-1-associated ARDS", "link": "https://www.thepharmaletter.com/article/incyte-says-phase-iii-jakafi-trial-misses-endpoint-for-covid-1-associated-ards", "pubDate": "2021-03-19 11:08:00"}, {"filename": "2-billion-boost-for-fujifilm-s-biologics-business.json", "title": "$2 billion boost for Fujifilm's biologics business", "description": "Another major manufacturing investment from Japanese conglomerate Fujifilm Corp will significantly boost its presence in cell culture production for biologic th", "link": "https://www.thepharmaletter.com/article/2-billion-boost-for-fujifilm-s-biologics-business", "pubDate": "2021-03-19 10:36:00"}, {"filename": "selexis-signs-license-deal-with-spybiotech-on-hcmv-vaccine-program.json", "title": "Selexis signs license deal with SpyBiotech on HCMV vaccine program", "description": "Selexis signs license deal with SpyBiotech on HCMV vaccine program", "link": "https://www.thepharmaletter.com/article/selexis-signs-license-deal-with-spybiotech-on-hcmv-vaccine-program", "pubDate": "2021-03-19 10:20:00"}, {"filename": "ema-view-unchanged-on-astrazeneca-jab-despite-possible-link-to-blood-clots.json", "title": "EMA view unchanged on AstraZeneca jab despite \u00e2\u0080\u0098possible link\u00e2\u0080\u0099 to blood clots", "description": NaN, "link": "https://www.thepharmaletter.com/article/ema-view-unchanged-on-astrazeneca-jab-despite-possible-link-to-blood-clots", "pubDate": "2021-03-18 18:09:00"}, {"filename": "takeda-inks-yet-another-deal-now-with-anima-worth-up-to-2-4-billion.json", "title": "Takeda inks yet another deal, now with Anima worth up to $2.4 billion", "description": "Takeda inks yet another deal, now with Anima worth up to $2.4 billion", "link": "https://www.thepharmaletter.com/article/takeda-inks-yet-another-deal-now-with-anima-worth-up-to-2-4-billion", "pubDate": "2021-03-18 17:30:00"}, {"filename": "gilead-and-novo-nordisk-expand-nash-collaboration.json", "title": "Gilead and Novo Nordisk expand NASH collaboration", "description": NaN, "link": "https://www.thepharmaletter.com/article/gilead-and-novo-nordisk-expand-nash-collaboration", "pubDate": "2021-03-18 16:06:00"}, {"filename": "gsk-in-out-licensing-deal-with-boston-pharmaceuticals.json", "title": "GSK in out-licensing deal with Boston Pharmaceuticals", "description": "UK pharma major GlaxoSmithKline will out-license and option programs to Boston Pharmaceuticals under a newly-announced agreement.", "link": "https://www.thepharmaletter.com/article/gsk-in-out-licensing-deal-with-boston-pharmaceuticals", "pubDate": "2021-03-18 15:44:00"}, {"filename": "merck-progresses-spinoff-of-organon.json", "title": "Merck progresses spinoff of Organon", "description": "Merck progresses spinoff of Organon", "link": "https://www.thepharmaletter.com/article/merck-progresses-spinoff-of-organon", "pubDate": "2021-03-18 15:31:00"}, {"filename": "pyxis-oncology-in-licenses-adc-candidates-from-pfizer.json", "title": "Pyxis Oncology in-licenses ADC candidates from Pfizer", "description": "Pyxis Oncology in-licenses ADC candidates from Pfizer", "link": "https://www.thepharmaletter.com/article/pyxis-oncology-in-licenses-adc-candidates-from-pfizer", "pubDate": "2021-03-18 14:28:00"}, {"filename": "novel-cystic-fibrosis-option-safe-but-no-sign-of-efficacy.json", "title": "Novel cystic fibrosis option safe, but no sign of efficacy", "description": "Translate Bio stock fell by a quarter in pre-market trading on Thursday, after interim data from a small trial testing mRNA candidate MRT5005 in cystic fibrosis", "link": "https://www.thepharmaletter.com/article/novel-cystic-fibrosis-option-safe-but-no-sign-of-efficacy", "pubDate": "2021-03-18 12:29:00"}, {"filename": "exec-change-at-merck-as-mike-nally-quits-top-marketing-job.json", "title": "Exec change at Merck, as Mike Nally quits top marketing job", "description": "Exec change at Merck, as Mike Nally quits top marketing job", "link": "https://www.thepharmaletter.com/article/exec-change-at-merck-as-mike-nally-quits-top-marketing-job", "pubDate": "2021-03-18 12:03:00"}, {"filename": "pfizer-to-quit-making-biosimilar-in-china-sells-out-to-wuxi.json", "title": "Pfizer to quit making biosimilar in China; sells out to WuXi", "description": "Pfizer to quit making biosimilar in China; sells out to WuXi", "link": "https://www.thepharmaletter.com/article/pfizer-to-quit-making-biosimilar-in-china-sells-out-to-wuxi", "pubDate": "2021-03-18 11:30:00"}, {"filename": "sobi-s-novel-peptide-beats-competition-in-rare-disease.json", "title": "Sobi's novel peptide beats competition in rare disease", "description": "Results from the Phase III PEGASUS trial have been published by Nordic rare diseases firm Swedish Orphan Biovitrum, also known as Sobi, and its partner Apellis ", "link": "https://www.thepharmaletter.com/article/sobi-s-novel-peptide-beats-competition-in-rare-disease", "pubDate": "2021-03-18 10:24:00"}, {"filename": "nice-backing-for-astrazeneca-s-calquence-in-cll.json", "title": "NICE backing for AstraZeneca\u00e2\u0080\u0099s Calquence in CLL", "description": "NICE backing for AstraZeneca\u00e2\u0080\u0099s Calquence in CLL", "link": "https://www.thepharmaletter.com/article/nice-backing-for-astrazeneca-s-calquence-in-cll", "pubDate": "2021-03-18 10:08:00"}, {"filename": "rising-chinese-prices-cause-india-s-nppa-to-hike-heparin-ceiling-price.json", "title": "Rising Chinese prices cause India\u00e2\u0080\u0099s NPPA to hike heparin ceiling price", "description": "Rising Chinese prices cause India\u00e2\u0080\u0099s NPPA to hike heparin ceiling price", "link": "https://www.thepharmaletter.com/article/rising-chinese-prices-cause-india-s-nppa-to-hike-heparin-ceiling-price", "pubDate": "2021-03-18 10:07:00"}, {"filename": "nice-nods-through-daiichi-sankyo-s-cholesterol-drugs.json", "title": "NICE nods through Daiichi Sankyo\u00e2\u0080\u0099s cholesterol drugs", "description": "The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the provision of Nilembo (bempedoic acid) ", "link": "https://www.thepharmaletter.com/article/nice-nods-through-daiichi-sankyo-s-cholesterol-drugs", "pubDate": "2021-03-18 00:01:00"}, {"filename": "fda-extends-review-period-for-rinvoq.json", "title": "FDA extends review period for Rinvoq sNDA", "description": "FDA extends review period for Rinvoq sNDA", "link": "https://www.thepharmaletter.com/article/fda-extends-review-period-for-rinvoq", "pubDate": "2021-03-17 17:45:00"}, {"filename": "chiesi-usa-announces-commercial-availability-of-bronchitol-in-usa.json", "title": "Chiesi USA announces commercial availability of Bronchitol in USA", "description": "Chiesi USA announces commercial availability of Bronchitol in USA", "link": "https://www.thepharmaletter.com/article/chiesi-usa-announces-commercial-availability-of-bronchitol-in-usa", "pubDate": "2021-03-17 16:51:00"}, {"filename": "expanded-keytruda-indication-in-eu-and-first-for-pediatric-patients.json", "title": "Expanded Keytruda indication in EU and first for pediatric patients", "description": "The European Commission (EC) has approved an expanded label for Keytruda (pembrolizumab) as monotherapy for adults and children aged three years and older with ", "link": "https://www.thepharmaletter.com/article/expanded-keytruda-indication-in-eu-and-first-for-pediatric-patients", "pubDate": "2021-03-17 15:07:00"}, {"filename": "sanofi-gains-rights-to-probiogen-s-glymaxx-technology.json", "title": "Sanofi gains rights to ProBioGen\u00e2\u0080\u0099s GlymaxX technology", "description": "Sanofi gains rights to ProBioGen\u00e2\u0080\u0099s GlymaxX technology", "link": "https://www.thepharmaletter.com/article/sanofi-gains-rights-to-probiogen-s-glymaxx-technology", "pubDate": "2021-03-17 14:55:00"}, {"filename": "more-positive-data-validate-lilly-s-big-bet-on-mirikizumab.json", "title": "More positive data validate Lilly's big bet on mirikizumab", "description": "Positive results from a trial of Eli Lilly\u00e2\u0080\u0099s monoclonal antibody mirikizumab raise the prospect of further competition in the gastrointestinal disorder space.", "link": "https://www.thepharmaletter.com/article/more-positive-data-validate-lilly-s-big-bet-on-mirikizumab", "pubDate": "2021-03-17 14:31:00"}, {"filename": "maat-to-move-microbiome-drug-into-phase-iii-trial.json", "title": "MaaT to move microbiome drug into Phase III trial", "description": "French microbiome company MaaT Pharma has announced topline results from a Phase II trial evaluating MaaT013 in a high-risk patient population with grade III-IV", "link": "https://www.thepharmaletter.com/article/maat-to-move-microbiome-drug-into-phase-iii-trial", "pubDate": "2021-03-17 14:13:00"}, {"filename": "eisai-inks-alzheimer-s-collaboration-with-dzne.json", "title": "Eisai inks Alzheimer\u00e2\u0080\u0099s collaboration with DZNE", "description": "Eisai inks Alzheimer\u00e2\u0080\u0099s collaboration with DZNE", "link": "https://www.thepharmaletter.com/article/eisai-inks-alzheimer-s-collaboration-with-dzne", "pubDate": "2021-03-17 14:00:00"}, {"filename": "vaccitech-completes-168-million-financing.json", "title": "Vaccitech completes $168 million financing", "description": "UK-based Vaccitech said today it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vacci", "link": "https://www.thepharmaletter.com/article/vaccitech-completes-168-million-financing", "pubDate": "2021-03-17 11:32:00"}, {"filename": "chief-medical-officer-jumps-ship-in-wake-of-bluebird-trial-stoppage.json", "title": "Chief medical officer jumps ship in wake of bluebird trial stoppage", "description": "In a filing with the US Securities and Exchange Commission (SEC), bluebird bio has announced the departure of its chief medical officer, David Davidson.", "link": "https://www.thepharmaletter.com/article/chief-medical-officer-jumps-ship-in-wake-of-bluebird-trial-stoppage", "pubDate": "2021-03-17 10:43:00"}, {"filename": "ftc-and-other-regulators-set-out-new-approach-to-pharma-m-a.json", "title": "FTC and other regulators set out new approach to pharma M&A", "description": "FTC and other regulators set out new approach to pharma M&A", "link": "https://www.thepharmaletter.com/article/ftc-and-other-regulators-set-out-new-approach-to-pharma-m-a", "pubDate": "2021-03-17 10:40:00"}, {"filename": "sandoz-in-licenses-authorized-generic-of-proventil-hfa.json", "title": "Sandoz in-licenses authorized generic of Proventil HFA", "description": "Sandoz in-licenses authorized generic of Proventil HFA", "link": "https://www.thepharmaletter.com/article/sandoz-in-licenses-authorized-generic-of-proventil-hfa", "pubDate": "2021-03-17 10:03:00"}, {"filename": "arm-highlights-record-rector-growth-and-resilience-in-2020.json", "title": "ARM highlights record rector growth and resilience in 2020", "description": "ARM highlights record rector growth and resilience in 2020", "link": "https://www.thepharmaletter.com/article/arm-highlights-record-rector-growth-and-resilience-in-2020", "pubDate": "2021-03-16 16:47:00"}, {"filename": "merck-takes-another-hit-on-bintrafusp-alfa-development.json", "title": "Merck takes another hit on bintrafusp alfa development", "description": "Merck takes another hit on bintrafusp alfa development", "link": "https://www.thepharmaletter.com/article/merck-takes-another-hit-on-bintrafusp-alfa-development", "pubDate": "2021-03-16 15:59:00"}, {"filename": "data-show-alternative-to-hospital-for-some-cabp-patients.json", "title": "Data show alternative to hospital for some CABP patients", "description": "Nabriva Therapeutics has published a post-hoc analysis of data from the Phase III LEAP 2 study of oral antibiotic Xenleta (lefamulin).", "link": "https://www.thepharmaletter.com/article/data-show-alternative-to-hospital-for-some-cabp-patients", "pubDate": "2021-03-16 15:56:00"}, {"filename": "genevant-nabs-600-million-deal-with-japan-s-takeda.json", "title": "Genevant nabs $600 million deal with Japan\u00e2\u0080\u0099s Takeda", "description": "Genevant nabs $600 million deal with Japan\u00e2\u0080\u0099s Takeda", "link": "https://www.thepharmaletter.com/article/genevant-nabs-600-million-deal-with-japan-s-takeda", "pubDate": "2021-03-16 14:07:00"}, {"filename": "orphan-drug-candidate-blossoms-in-japan.json", "title": "Orphan drug candidate blossoms in Japan", "description": "A novel treatment for the viral disease CMV viremia, TAK-620 (maribavir), has generated positive results in the Phase III SOLSTICE trial.", "link": "https://www.thepharmaletter.com/article/orphan-drug-candidate-blossoms-in-japan", "pubDate": "2021-03-16 12:38:00"}, {"filename": "thromboembolic-events-don-t-appear-higher-in-vaccinated-population-ema-says.json", "title": "Thromboembolic events don\u00e2\u0080\u0099t appear higher in vaccinated population, EMA says", "description": "As of lunchtime on Tuesday, 11 European countries had halted the rollout of COVID-19 Vaccine AstraZeneca after a number of cases of blood clots.", "link": "https://www.thepharmaletter.com/article/thromboembolic-events-don-t-appear-higher-in-vaccinated-population-ema-says", "pubDate": "2021-03-16 12:31:00"}, {"filename": "medicago-and-gsk-launch-phase-iii-trial-of-adjuvanted-covid-19-vaccine-candidate.json", "title": "Medicago and GSK launch Phase III trial of adjuvanted COVID-19 vaccine candidate", "description": "Medicago and GSK launch Phase III trial of adjuvanted COVID-19 vaccine candidate", "link": "https://www.thepharmaletter.com/article/medicago-and-gsk-launch-phase-iii-trial-of-adjuvanted-covid-19-vaccine-candidate", "pubDate": "2021-03-16 12:07:00"}, {"filename": "otsuka-partners-with-atai-unit-on-alternative-ketamine-based-treatments-for-depression.json", "title": "Otsuka partners with atai unit on alternative ketamine-based treatments for depression", "description": "Otsuka partners with atai unit on alternative ketamine-based treatments for depression", "link": "https://www.thepharmaletter.com/article/otsuka-partners-with-atai-unit-on-alternative-ketamine-based-treatments-for-depression", "pubDate": "2021-03-16 11:26:00"}, {"filename": "two-year-data-detail-impact-of-evrysdi-in-sma.json", "title": "Two-year data detail impact of Evrysdi in SMA", "description": "Basel\u00e2\u0080\u0099s Roche has announced new exploratory two-year data from the SUNFISH study of Evrysdi (risdiplam) in spinal muscular atrophy (SMA).", "link": "https://www.thepharmaletter.com/article/two-year-data-detail-impact-of-evrysdi-in-sma", "pubDate": "2021-03-16 10:36:00"}, {"filename": "astrazeneca-inks-new-205-million-deal-with-us-govt-for-covid-19-antibody-azd7442.json", "title": "AstraZeneca inks new $205 million deal with US govt for COVID-19 antibody AZD7442", "description": "AstraZeneca inks new $205 million deal with US govt for COVID-19 antibody AZD7442", "link": "https://www.thepharmaletter.com/article/astrazeneca-inks-new-205-million-deal-with-us-govt-for-covid-19-antibody-azd7442", "pubDate": "2021-03-16 10:21:00"}, {"filename": "russia-plans-new-strategy-for-pharmaceutical-sector-until-2030.json", "title": "Russia plans new strategy for pharmaceutical sector until 2030", "description": "Russia plans new strategy for pharmaceutical sector until 2030", "link": "https://www.thepharmaletter.com/article/russia-plans-new-strategy-for-pharmaceutical-sector-until-2030", "pubDate": "2021-03-16 10:20:00"}, {"filename": "biocad-eyes-production-of-its-forteka-cancer-drug-in-china.json", "title": "Biocad eyes production of its Forteka cancer drug in China", "description": "Biocad eyes production of its Forteka cancer drug in China", "link": "https://www.thepharmaletter.com/article/biocad-eyes-production-of-its-forteka-cancer-drug-in-china", "pubDate": "2021-03-15 17:26:00"}, {"filename": "elevatebio-bags-huge-525-million-in-series-c-round.json", "title": "ElevateBio bags huge $525 million in Series C round", "description": "Cell and gene therapy technology company ElevateBio has raised $525 million in a Series C financing.", "link": "https://www.thepharmaletter.com/article/elevatebio-bags-huge-525-million-in-series-c-round", "pubDate": "2021-03-15 16:39:00"}, {"filename": "real-world-zolgensma-data-reinforces-transformational-profile.json", "title": "Real-world Zolgensma data reinforces transformational profile", "description": "Swiss pharma giant Novartis has announced new data that reinforces the transformational benefit of Zolgensma (onasemnogene abeparvovec), a one-time gene therapy", "link": "https://www.thepharmaletter.com/article/real-world-zolgensma-data-reinforces-transformational-profile", "pubDate": "2021-03-15 15:00:00"}, {"filename": "aveo-oncology-to-regain-ex-north-american-rights-to-av-203.json", "title": "AVEO Oncology to regain ex-North American rights to AV-203", "description": "AVEO Oncology to regain ex-North American rights to AV-203", "link": "https://www.thepharmaletter.com/article/aveo-oncology-to-regain-ex-north-american-rights-to-av-203", "pubDate": "2021-03-15 14:22:00"}, {"filename": "clinigen-and-amgen-agree-multi-product-distribution-deal.json", "title": "Clinigen and Amgen agree multi-product distribution deal", "description": "UK-based Clinigen Group (AIM: CLIN) has signed a distribution agreement with Amgen (Nasdaq: AMGN) to supply part of its product portfolio to multiple countries ", "link": "https://www.thepharmaletter.com/article/clinigen-and-amgen-agree-multi-product-distribution-deal", "pubDate": "2021-03-15 14:13:00"}, {"filename": "high-tumor-mutation-burden-only-predicts-when-immunotherapy-will-work-in-certain-cancers.json", "title": "High tumor mutation burden only predicts when immunotherapy will work in certain cancers", "description": "A new study led by researchers from The University of Texas MD Anderson Cancer Center has shed some light on the matter of predicting when immunotherapies will ", "link": "https://www.thepharmaletter.com/article/high-tumor-mutation-burden-only-predicts-when-immunotherapy-will-work-in-certain-cancers", "pubDate": "2021-03-15 13:50:00"}, {"filename": "merck-and-gilead-partner-on-hiv-treatment-combo.json", "title": "Rivals Merck and Gilead partner on HIV treatment combo", "description": "Merck and Gilead partner on HIV treatment combo", "link": "https://www.thepharmaletter.com/article/merck-and-gilead-partner-on-hiv-treatment-combo", "pubDate": "2021-03-15 12:46:00"}, {"filename": "trial-of-libtayo-stopped-early-on-strong-phase-iii-data.json", "title": "Trial of Libtayo stopped early on strong Phase III data", "description": "Trial of Libtayo stopped early on strong Phase III data", "link": "https://www.thepharmaletter.com/article/trial-of-libtayo-stopped-early-on-strong-phase-iii-data", "pubDate": "2021-03-15 12:19:00"}, {"filename": "rdif-ceo-explains-sputnik-v-developments.json", "title": "RDIF CEO explains Sputnik V developments", "description": "RDIF CEO explains Sputnik V developments", "link": "https://www.thepharmaletter.com/article/rdif-ceo-explains-sputnik-v-developments", "pubDate": "2021-03-15 10:47:00"}, {"filename": "cheaper-cancer-drug-battle-stoked-up-in-india.json", "title": "Cheaper cancer drug battle stoked up in India", "description": "Cheaper cancer drug battle stoked up in India", "link": "https://www.thepharmaletter.com/article/cheaper-cancer-drug-battle-stoked-up-in-india", "pubDate": "2021-03-15 10:31:00"}, {"filename": "mixed-but-encouraging-results-for-lilly-s-donanemab-in-alzheimer-s.json", "title": "Mixed but encouraging results for Lilly's donanemab in Alzheimer's", "description": "Mixed but encouraging results for Lilly's donanemab in Alzheimer's", "link": "https://www.thepharmaletter.com/article/mixed-but-encouraging-results-for-lilly-s-donanemab-in-alzheimer-s", "pubDate": "2021-03-15 10:30:00"}, {"filename": "swedish-firm-breaking-new-ground-in-rare-kidney-condition.json", "title": "Swedish firm breaking new ground in rare kidney condition", "description": "Stockholm\u00e2\u0080\u0099s Calliditas Therapeutics has completed its US regulatory submission for Nefecon (budesonide), an oral treatment of primary IgA Nephropathy (IgAN).", "link": "https://www.thepharmaletter.com/article/swedish-firm-breaking-new-ground-in-rare-kidney-condition", "pubDate": "2021-03-15 10:27:00"}, {"filename": "look-back-at-pharma-news-in-the-week-to-march-12-2021.json", "title": "Look back at pharma news in the week to March 12, 2021", "description": "Look back at pharma news in the week to March 12, 2021", "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-march-12-2021", "pubDate": "2021-03-14 10:30:00"}, {"filename": "icer-finds-benefits-for-benlysta-and-lupkynis-in-lupus-nephritis.json", "title": "ICER finds benefits for Benlysta and Lupkynis in Lupus nephritis", "description": "ICER finds benefits for Benlysta and Lupkynis in Lupus nephritis", "link": "https://www.thepharmaletter.com/article/icer-finds-benefits-for-benlysta-and-lupkynis-in-lupus-nephritis", "pubDate": "2021-03-13 16:08:00"}, {"filename": "prac-begins-safety-review-of-bluebird-bio-s-zynteglo.json", "title": "PRAC begins safety review of bluebird bio\u00e2\u0080\u0099s Zynteglo", "description": NaN, "link": "https://www.thepharmaletter.com/article/prac-begins-safety-review-of-bluebird-bio-s-zynteglo", "pubDate": "2021-03-12 17:48:00"}, {"filename": "ema-s-prac-tries-to-placate-fears-on-covid-19-vaccine-astrazeneca.json", "title": "EMA\u00e2\u0080\u0099s PRAC tries to placate fears on COVID-19 Vaccine AstraZeneca", "description": NaN, "link": "https://www.thepharmaletter.com/article/ema-s-prac-tries-to-placate-fears-on-covid-19-vaccine-astrazeneca", "pubDate": "2021-03-12 16:42:00"}, {"filename": "boehringer-drops-development-of-a-covid-19-candidate.json", "title": "Boehringer drops development of a COVID-19 candidate", "description": "Boehringer drops development of a COVID-19 candidate", "link": "https://www.thepharmaletter.com/article/boehringer-drops-development-of-a-covid-19-candidate", "pubDate": "2021-03-12 16:11:00"}, {"filename": "international-supply-contracts-supplying-peter-and-snubbing-paul.json", "title": "International supply contracts: supplying Peter and snubbing Paul?", "description": "Catherine Penny, partner, and Laura Beagrie, professional support lawyer, Stevens & Bolton, consider an important issue brought to light by the scramble for cor", "link": "https://www.thepharmaletter.com/article/international-supply-contracts-supplying-peter-and-snubbing-paul", "pubDate": "2021-03-12 15:44:00"}, {"filename": "apn01-shows-clinical-benefits-for-severely-ill-covid-19-patients.json", "title": "APN01 shows clinical benefits for severely ill COVID-19 patients", "description": "APN01 shows clinical benefits for severely ill COVID-19 patients", "link": "https://www.thepharmaletter.com/article/apn01-shows-clinical-benefits-for-severely-ill-covid-19-patients", "pubDate": "2021-03-12 15:27:00"}, {"filename": "aveo-oncology-inks-deal-with-bms-to-study-kidney-cancer-combo.json", "title": "AVEO Oncology inks deal with BMS to study kidney cancer combo", "description": "AVEO Oncology inks deal with BMS to study kidney cancer combo", "link": "https://www.thepharmaletter.com/article/aveo-oncology-inks-deal-with-bms-to-study-kidney-cancer-combo", "pubDate": "2021-03-12 14:49:00"}, {"filename": "high-value-deals-make-chinese-oncology-market-a-good-place-to-be.json", "title": "High-value deals make Chinese oncology market a good place to be", "description": "The Asia-Pacific (APAC) pharmaceutical strategic partnership landscape in 2020 was dominated by high-value deals, with Chinese oncology a particularly lucrative", "link": "https://www.thepharmaletter.com/article/high-value-deals-make-chinese-oncology-market-a-good-place-to-be", "pubDate": "2021-03-12 12:45:00"}, {"filename": "takeda-files-japan-nda-for-lanadelumab-for-hae.json", "title": "Takeda files Japan NDA for lanadelumab for HAE", "description": "Takeda files Japan NDA for lanadelumab for HAE", "link": "https://www.thepharmaletter.com/article/takeda-files-japan-nda-for-lanadelumab-for-hae", "pubDate": "2021-03-12 12:14:00"}, {"filename": "another-string-to-the-bow-in-global-pandemic-fight.json", "title": "Another string to the bow in global pandemic fight", "description": "Positive Phase III data from East Coast, USA-based vaccine specialist Novavax could soon pave the way for another approved option against the novel coronavirus.", "link": "https://www.thepharmaletter.com/article/another-string-to-the-bow-in-global-pandemic-fight", "pubDate": "2021-03-12 11:32:00"}, {"filename": "takeda-s-growth-plan-foresees-revenues-of-9-billion-for-gem-bu-in-2030.json", "title": "Takeda\u00e2\u0080\u0099s growth plan foresees revenues of ~$9 billion for GEM-BU in 2030", "description": "Takeda\u00e2\u0080\u0099s growth plan foresees revenues of ~$9 billion for GEM-BU in 2030", "link": "https://www.thepharmaletter.com/article/takeda-s-growth-plan-foresees-revenues-of-9-billion-for-gem-bu-in-2030", "pubDate": "2021-03-12 10:39:00"}, {"filename": "usa-pledges-3-5-billion-emergency-investment-to-global-fund-to-fight-covid-19.json", "title": "USA pledges $3.5 billion emergency investment to Global Fund to fight COVID-19", "description": "USA pledges $3.5 billion emergency investment to Global Fund to fight COVID-19", "link": "https://www.thepharmaletter.com/article/usa-pledges-3-5-billion-emergency-investment-to-global-fund-to-fight-covid-19", "pubDate": "2021-03-12 10:14:00"}, {"filename": "covid-19-vaccine-janssen-becomes-4th-backed-for-authorization-by-ema.json", "title": "COVID-19 Vaccine Janssen becomes 4th backed for authorization by EMA", "description": "COVID-19 Vaccine Janssen becomes 4th backed for authorization by EMA", "link": "https://www.thepharmaletter.com/article/covid-19-vaccine-janssen-becomes-4th-backed-for-authorization-by-ema", "pubDate": "2021-03-11 16:41:00"}, {"filename": "positive-phase-iii-results-for-lilly-s-bamlanivimab-and-etesevimab-for-early-covid-19.json", "title": "Positive Phase III results for Lilly's bamlanivimab and etesevimab for early COVID-19", "description": "Positive Phase III results for Lilly's bamlanivimab and etesevimab for early COVID-19", "link": "https://www.thepharmaletter.com/article/positive-phase-iii-results-for-lilly-s-bamlanivimab-and-etesevimab-for-early-covid-19", "pubDate": "2021-03-11 15:50:00"}, {"filename": "stada-arz-achieves-15-profit-growth-to-713-million-euros.json", "title": "STADA Arz achieves 15% profit growth to 713 million euros", "description": "STADA Arz achieves 15% profit growth to 713 million euros", "link": "https://www.thepharmaletter.com/article/stada-arz-achieves-15-profit-growth-to-713-million-euros", "pubDate": "2021-03-11 15:03:00"}, {"filename": "doctors-call-for-clarity-amid-opposing-astrazeneca-vaccine-views.json", "title": "Doctors call for clarity amid opposing AstraZeneca vaccine views", "description": "Health authorities in European Union (EU) countries have intervened amid concerns around the safety of the AstraZeneca COVID-19 vaccine.", "link": "https://www.thepharmaletter.com/article/doctors-call-for-clarity-amid-opposing-astrazeneca-vaccine-views", "pubDate": "2021-03-11 12:58:00"}, {"filename": "astellas-files-for-japanese-approval-of-enfortumab-vedotin.json", "title": "Astellas files for Japanese approval of enfortumab vedotin", "description": "Astellas files for Japanese approval of enfortumab vedotin", "link": "https://www.thepharmaletter.com/article/astellas-files-for-japanese-approval-of-enfortumab-vedotin", "pubDate": "2021-03-11 12:41:00"}, {"filename": "bayer-anticipates-immediate-pharma-bounce-back-after-2024-blip.json", "title": "Bayer anticipates immediate pharma bounce back after 2024 blip", "description": "German company Bayer is confident that it can bounce back from a decline in the Pharmaceuticals division\u00e2\u0080\u0099s sales in 2024 due to the patent expirations for estab", "link": "https://www.thepharmaletter.com/article/bayer-anticipates-immediate-pharma-bounce-back-after-2024-blip", "pubDate": "2021-03-11 11:28:00"}, {"filename": "long-awaited-fda-approval-for-aveo-oncology-s-fotivda.json", "title": "Long-awaited FDA approval for AVEO Oncology's Fotivda", "description": "Long-awaited FDA approval for AVEO Oncology's Fotivda", "link": "https://www.thepharmaletter.com/article/long-awaited-fda-approval-for-aveo-oncology-s-fotivda", "pubDate": "2021-03-11 11:06:00"}, {"filename": "end-to-gsk-losing-streak-brings-hope-for-covid-19-patients.json", "title": "End to GSK losing streak brings hope for COVID-19 patients", "description": "Positive Phase III data herald a significant turnaround in the fortunes of GlaxoSmithKline\u00e2\u0080\u0099s coronavirus program.", "link": "https://www.thepharmaletter.com/article/end-to-gsk-losing-streak-brings-hope-for-covid-19-patients", "pubDate": "2021-03-11 10:27:00"}, {"filename": "roche-says-remdacta-trial-misses-in-severe-covid-19-pneumonia.json", "title": "Roche says REMDACTA trial misses in severe COVID-19 pneumonia", "description": "Roche says REMDACTA trial misses in severe COVID-19 pneumonia", "link": "https://www.thepharmaletter.com/article/roche-says-remdacta-trial-misses-in-severe-covid-19-pneumonia", "pubDate": "2021-03-11 10:13:00"}, {"filename": "pricing-and-regulatory-challenges-impact-revenue-new-study-reveals.json", "title": "Pricing and regulatory challenges impact revenue, new study reveals", "description": "Pricing and regulatory challenges impact revenue, new study reveals", "link": "https://www.thepharmaletter.com/article/pricing-and-regulatory-challenges-impact-revenue-new-study-reveals", "pubDate": "2021-03-11 10:11:00"}, {"filename": "bluebird-bio-says-very-unlikely-aml-events-are-linked-to-its-gene-therapy.json", "title": "bluebird bio says \u00e2\u0080\u0098very unlikely\u00e2\u0080\u0099 AML events are linked to its gene therapy", "description": "Shares of US biotech bluebird bio (Nasdaq: BLUE) gained 13% pre-market today and were still up 8.8% at $32.70 by mid-morning after it announced encouraging anal", "link": "https://www.thepharmaletter.com/article/bluebird-bio-says-very-unlikely-aml-events-are-linked-to-its-gene-therapy", "pubDate": "2021-03-10 17:39:00"}, {"filename": "complix-bags-i-mab-deal.json", "title": "Complix bags I-Mab deal", "description": "Belgian biopharma Complix has signed a drug discovery deal with Chinese immuno-oncology (I-O) specialist I-Mab.", "link": "https://www.thepharmaletter.com/article/complix-bags-i-mab-deal", "pubDate": "2021-03-10 16:45:00"}, {"filename": "agomab-therapeutics-raises-74-million-series-b-financing.json", "title": "AgomAb Therapeutics raises $74 million in Series B financing", "description": "AgomAb Therapeutics raises $74 million Series B financing", "link": "https://www.thepharmaletter.com/article/agomab-therapeutics-raises-74-million-series-b-financing", "pubDate": "2021-03-10 16:15:00"}, {"filename": "canakinumab-results-disappoint-but-other-studies-go-on.json", "title": "Canakinumab results disappoint but other studies go on", "description": "Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab in combination with the chemotherapy agent docetaxel, did not meet its primary e", "link": "https://www.thepharmaletter.com/article/canakinumab-results-disappoint-but-other-studies-go-on", "pubDate": "2021-03-10 15:40:00"}, {"filename": "incorporating-quality-of-life-measures-into-drug-approvals-what-is-the-fda-s-stance.json", "title": "Incorporating quality of life measures into drug approvals: What is the FDA\u00e2\u0080\u0099s Stance?", "description": "Incorporating quality of life measures into drug approvals: What is the FDA\u00e2\u0080\u0099s Stance?", "link": "https://www.thepharmaletter.com/article/incorporating-quality-of-life-measures-into-drug-approvals-what-is-the-fda-s-stance", "pubDate": "2021-03-10 15:09:00"}, {"filename": "uni-bio-science-and-dotbio-partner-on-retinal-diseases.json", "title": "Uni-Bio Science and DotBio partner on retinal diseases", "description": "Uni-Bio Science and DotBio partner on retinal diseases", "link": "https://www.thepharmaletter.com/article/uni-bio-science-and-dotbio-partner-on-retinal-diseases", "pubDate": "2021-03-10 14:37:00"}, {"filename": "alarm-bells-over-fda-inspections-backlog.json", "title": "Alarm bells over FDA inspections backlog", "description": "The US Government Accountability Office (GAO) has called on the US Food and Drug Administration (FDA) to address a backlog in inspections that has been worsened", "link": "https://www.thepharmaletter.com/article/alarm-bells-over-fda-inspections-backlog", "pubDate": "2021-03-10 12:50:00"}, {"filename": "abbvie-pips-gilead-to-dominate-japan-s-hepatitis-c-virus-digital-marketing-space.json", "title": "AbbVie pips Gilead to dominate Japan\u00e2\u0080\u0099s hepatitis C virus digital marketing space", "description": "AbbVie pips Gilead to dominate Japan\u00e2\u0080\u0099s hepatitis C virus digital marketing space", "link": "https://www.thepharmaletter.com/article/abbvie-pips-gilead-to-dominate-japan-s-hepatitis-c-virus-digital-marketing-space", "pubDate": "2021-03-10 12:27:00"}, {"filename": "drug-delivery-tech-could-transform-treatment-of-covid-19.json", "title": "Drug delivery tech could transform treatment of COVID-19", "description": "Drug delivery innovator TFF Pharmaceuticals, a biotech company based in Texas, has entered into two new collaborations exploring the use of its technology.", "link": "https://www.thepharmaletter.com/article/drug-delivery-tech-could-transform-treatment-of-covid-19", "pubDate": "2021-03-10 11:52:00"}, {"filename": "rocket-rises-as-it-receives-rmat-status-for-lad-i-gene-therapy.json", "title": "Rocket rises as it receives RMAT status for LAD-I gene therapy", "description": "Rocket rises as it receives RMAT status for LAD-I gene therapy", "link": "https://www.thepharmaletter.com/article/rocket-rises-as-it-receives-rmat-status-for-lad-i-gene-therapy", "pubDate": "2021-03-10 11:40:00"}, {"filename": "first-in-class-hiv-drug-can-overcome-multi-drug-resistance.json", "title": "First-in-class HIV drug can overcome multi-drug resistance", "description": "A new long-acting HIV treatment under development by Gilead Sciences has produced positive results through 26 weeks in the Phase II/III CAPELLA trial.", "link": "https://www.thepharmaletter.com/article/first-in-class-hiv-drug-can-overcome-multi-drug-resistance", "pubDate": "2021-03-10 10:07:00"}, {"filename": "orionis-in-drug-discovery-tie-up-with-md-anderson.json", "title": "Orionis in drug discovery tie-up with MD Anderson", "description": "Orionis Biosciences, a privately-held genome-scale drug discovery company, and The University of Texas MD Anderson Cancer Center\u00e2\u0080\u0099s Therapeutics Discovery divisi", "link": "https://www.thepharmaletter.com/article/orionis-in-drug-discovery-tie-up-with-md-anderson", "pubDate": "2021-03-09 16:54:00"}, {"filename": "india-s-sii-seeks-govt-intervention-over-covid-vaccine-raw-material-import-from-usa.json", "title": "India\u00e2\u0080\u0099s SII seeks govt intervention over COVID vaccine raw material import from USA", "description": "India\u00e2\u0080\u0099s SII seeks govt intervention over COVID vaccine raw material import from USA", "link": "https://www.thepharmaletter.com/article/india-s-sii-seeks-govt-intervention-over-covid-vaccine-raw-material-import-from-usa", "pubDate": "2021-03-09 16:36:00"}, {"filename": "ptc-therapeutics-and-sma-foundation-to-collaborate-on-regenerative-medicine.json", "title": "PTC Therapeutics and SMA Foundation to collaborate on regenerative medicine", "description": "PTC Therapeutics and SMA Foundation to collaborate on regenerative medicine", "link": "https://www.thepharmaletter.com/article/ptc-therapeutics-and-sma-foundation-to-collaborate-on-regenerative-medicine", "pubDate": "2021-03-09 15:53:00"}, {"filename": "grifols-acquires-remaining-56-of-the-us-biopharma-gigagen.json", "title": "Grifols acquires remaining 56% of the US biopharma GigaGen", "description": "Grifols acquires remaining 56% of the US biopharma GigaGen", "link": "https://www.thepharmaletter.com/article/grifols-acquires-remaining-56-of-the-us-biopharma-gigagen", "pubDate": "2021-03-09 14:59:00"}, {"filename": "takeda-exercises-option-to-buy-maverick.json", "title": "Takeda exercises option to buy Maverick", "description": "Japanese drugmaker Takeda has announced the exercise of its option to acquire Maverick Therapeutics, a private biopharma company pioneering conditionally active", "link": "https://www.thepharmaletter.com/article/takeda-exercises-option-to-buy-maverick", "pubDate": "2021-03-09 13:11:00"}, {"filename": "soleno-tanks-as-fda-calls-for-additional-trial-of-prader-willi-candidate.json", "title": "Soleno tanks as FDA calls for additional trial of Prader-Willi candidate", "description": "Soleno tanks as FDA calls for additional trial of Prader-Willi candidate", "link": "https://www.thepharmaletter.com/article/soleno-tanks-as-fda-calls-for-additional-trial-of-prader-willi-candidate", "pubDate": "2021-03-09 12:39:00"}, {"filename": "regulatory-wobble-unnerves-acadia-backers.json", "title": "Regulatory wobble unnerves Acadia backers", "description": "Stumbling 7% before the closing bell on Monday, shares in San Diego\u00e2\u0080\u0099s Acadia Pharmaceuticals fell a further 38% in after-hours trading, following a regulatory s", "link": "https://www.thepharmaletter.com/article/regulatory-wobble-unnerves-acadia-backers", "pubDate": "2021-03-09 11:50:00"}, {"filename": "phase-iii-trial-for-leronlimab-in-covid-19-patients-disappoints.json", "title": "Phase III trial for leronlimab in COVID-19 patients disappoints", "description": "Phase III trial for leronlimab in COVID-19 patients disappoints", "link": "https://www.thepharmaletter.com/article/phase-iii-trial-for-leronlimab-in-covid-19-patients-disappoints", "pubDate": "2021-03-09 11:19:00"}, {"filename": "what-will-be-2021-s-most-game-changing-new-drugs.json", "title": "What will be 2021's most game-changing new drugs?", "description": "What will be 2021's most game-changing new drugs?", "link": "https://www.thepharmaletter.com/article/what-will-be-2021-s-most-game-changing-new-drugs", "pubDate": "2021-03-09 10:25:00"}, {"filename": "vaccines-seem-effective-against-brazilian-variant.json", "title": "Vaccines seem effective against Brazilian variant", "description": "Lab research published in the New England Journal of Medicine suggests that Comirnaty, the coronavirus vaccine developed by BioNTech and Pfizer, could be effect", "link": "https://www.thepharmaletter.com/article/vaccines-seem-effective-against-brazilian-variant", "pubDate": "2021-03-09 09:36:00"}, {"filename": "more-efforts-to-reduce-russian-pharma-dependence-on-api-imports.json", "title": "More efforts to reduce Russian pharma dependence on API imports", "description": "More efforts to reduce Russian pharma dependence on API imports", "link": "https://www.thepharmaletter.com/article/more-efforts-to-reduce-russian-pharma-dependence-on-api-imports", "pubDate": "2021-03-08 15:54:00"}, {"filename": "exelixis-enters-licensing-deal-with-wuxi-biologics.json", "title": "Exelixis enters licensing deal with Wuxi Biologics", "description": "Genomics-based drug discovery company Exelixis has announced an exclusive license agreement with WuXi Bio to support the continued expansion of its oncology bio", "link": "https://www.thepharmaletter.com/article/exelixis-enters-licensing-deal-with-wuxi-biologics", "pubDate": "2021-03-08 15:04:00"}, {"filename": "nhs-england-bypasses-nice-by-agreeing-deal-on-zolgensma.json", "title": "NHS England bypasses NICE by agreeing deal on Zolgensma", "description": "The National Health Service (NHS) has fast-tracked the introduction of Novartis\u00e2\u0080\u0099 Zolgensma (onasemnogene abeparvovec) to make it available for babies and young ", "link": "https://www.thepharmaletter.com/article/nhs-england-bypasses-nice-by-agreeing-deal-on-zolgensma", "pubDate": "2021-03-08 13:02:00"}, {"filename": "ema-advisory-panel-backs-use-of-lilly-s-antibody-cocktail-for-covid-19.json", "title": "EMA advisory panel backs use of Lilly\u00e2\u0080\u0099s antibody cocktail for COVID-19", "description": "EMA advisory panel backs use of Lilly\u00e2\u0080\u0099s antibody cocktail for COVID-19", "link": "https://www.thepharmaletter.com/article/ema-advisory-panel-backs-use-of-lilly-s-antibody-cocktail-for-covid-19", "pubDate": "2021-03-08 12:34:00"}, {"filename": "super-blockbuster-biktarvy-backed-by-more-positive-data.json", "title": "Super-blockbuster Biktarvy backed by more positive data", "description": "Gilead Sciences has announced new, long-term data from open-label extensions of two Phase III studies of Biktarvy (bictegravir/emtricitabine/tenofovir alafenami", "link": "https://www.thepharmaletter.com/article/super-blockbuster-biktarvy-backed-by-more-positive-data", "pubDate": "2021-03-08 11:44:00"}, {"filename": "stada-arz-launches-medical-cannabis-under-the-brand-cannabistada.json", "title": "Stada Arz launches medical cannabis under the brand CannabiStada", "description": "Stada Arz launches medical cannabis under the brand CannabiStada", "link": "https://www.thepharmaletter.com/article/stada-arz-launches-medical-cannabis-under-the-brand-cannabistada", "pubDate": "2021-03-08 11:38:00"}, {"filename": "us-fda-tightens-ship-on-accelerated-approval-scheme.json", "title": "US FDA tightens ship on Accelerated Approval scheme", "description": "A third pharma major in as many weeks has voluntarily withdrawn from an immuno-oncology indication, as the US regulator toughens its stance towards Accelerated ", "link": "https://www.thepharmaletter.com/article/us-fda-tightens-ship-on-accelerated-approval-scheme", "pubDate": "2021-03-08 10:33:00"}, {"filename": "korsuva-accepted-for-fda-priority-review-in-pruritis.json", "title": "Korsuva accepted for FDA priority review in pruritis", "description": "Korsuva accepted for FDA priority review in pruritis", "link": "https://www.thepharmaletter.com/article/korsuva-accepted-for-fda-priority-review-in-pruritis", "pubDate": "2021-03-08 10:19:00"}, {"filename": "preliminary-phase-iia-trial-results-of-molnupiravir-in-covid-19.json", "title": "Preliminary Phase IIa trial results of molnupiravir in COVID-19", "description": "Preliminary Phase IIa trial results of molnupiravir in COVID-19", "link": "https://www.thepharmaletter.com/article/preliminary-phase-iia-trial-results-of-molnupiravir-in-covid-19", "pubDate": "2021-03-08 10:16:00"}, {"filename": "new-safety-readouts-boost-jyseleca-s-prospects-in-the-us-says-analyst.json", "title": "New safety readouts boost Jyseleca\u00e2\u0080\u0099s prospects in the US, says analyst", "description": "New safety readouts boost Jyseleca\u00e2\u0080\u0099s prospects in the US, says analyst", "link": "https://www.thepharmaletter.com/article/new-safety-readouts-boost-jyseleca-s-prospects-in-the-us-says-analyst", "pubDate": "2021-03-08 10:15:00"}, {"filename": "look-back-at-pharma-news-in-the-week-to-march-5-2021.json", "title": "Look back at pharma news in the week to March 5, 2021", "description": "Look back at pharma news in the week to March 5, 2021", "link": "https://www.thepharmaletter.com/article/look-back-at-pharma-news-in-the-week-to-march-5-2021", "pubDate": "2021-03-07 13:46:00"}, {"filename": "us-fda-approves-new-indication-for-yescarta.json", "title": "US FDA approves new indication for Yescarta", "description": "US FDA approves new indication for Yescarta", "link": "https://www.thepharmaletter.com/article/us-fda-approves-new-indication-for-yescarta", "pubDate": "2021-03-06 14:33:00"}, {"filename": "plasma-derived-therapies-and-the-fight-against-covid-19.json", "title": "Plasma-derived therapies and the fight against COVID-19", "description": "Patrick Delavault, executive VP, scientific & medical affairs, LFB Biopharmaceuticals, provides an Expert View on how the\u00c2\u00a0pandemic has led to a focus on an impo", "link": "https://www.thepharmaletter.com/article/plasma-derived-therapies-and-the-fight-against-covid-19", "pubDate": "2021-03-05 17:35:00"}, {"filename": "rebranded-revolo-biotherapeutics-showcases-its-plans.json", "title": "Rebranded Revolo Biotherapeutics showcases its plans", "description": "Rebranded Revolo Biotherapeutics showcases its plans", "link": "https://www.thepharmaletter.com/article/rebranded-revolo-biotherapeutics-showcases-its-plans", "pubDate": "2021-03-05 15:45:00"}, {"filename": "challenger-set-to-upset-novo-s-dominance-in-glp-1-class.json", "title": "Challenger set to upset Novo Nordisk's dominance in GLP-1 class", "description": "Shares in diabetes giant Novo Nordisk fell back 4% on Thursday, after its blockbuster Ozempic (semaglutide) was outshone in a head-to-head study.", "link": "https://www.thepharmaletter.com/article/challenger-set-to-upset-novo-s-dominance-in-glp-1-class", "pubDate": "2021-03-05 14:14:00"}, {"filename": "manta-ray-gives-hope-for-future-of-filgotinib.json", "title": "MANTA-RAy gives hope for future of filgotinib", "description": "Interim data from the MANTA-RAy and MANTA safety studies will help calm nerves at Belgian biotech Galapagos, with data pointing in the right direction for filgo", "link": "https://www.thepharmaletter.com/article/manta-ray-gives-hope-for-future-of-filgotinib", "pubDate": "2021-03-05 14:08:00"}, {"filename": "fibrogen-and-astrazeneca-s-roxadustat-to-face-fda-adcom.json", "title": "FibroGen and AstraZeneca\u00e2\u0080\u0099s roxadustat to face FDA AdCom", "description": "FibroGen and AstraZeneca\u00e2\u0080\u0099s roxadustat to face FDA AdCom", "link": "https://www.thepharmaletter.com/article/fibrogen-and-astrazeneca-s-roxadustat-to-face-fda-adcom", "pubDate": "2021-03-05 13:57:00"}, {"filename": "stada-arz-names-global-head-of-specialties.json", "title": "Stada Arz names global head of specialties", "description": "Stada Arz names global head of specialties", "link": "https://www.thepharmaletter.com/article/stada-arz-names-global-head-of-specialties", "pubDate": "2021-03-05 12:18:00"}, {"filename": "fda-approves-use-of-actemra-roactemra-in-interstitial-lung-disease.json", "title": "FDA approves use of Actemra/RoActemra in interstitial lung disease", "description": "FDA approves use of Actemra/RoActemra in interstitial lung disease", "link": "https://www.thepharmaletter.com/article/fda-approves-use-of-actemra-roactemra-in-interstitial-lung-disease", "pubDate": "2021-03-05 11:05:00"}, {"filename": "humanitarian-mechanism-unlocks-rotarix-for-emergency-use.json", "title": "Humanitarian Mechanism unlocks Rotarix for emergency use", "description": "British drugmaker GlaxoSmithKline (LSE: GSK) has reached a humanitarian pricing agreement to make its rotavirus vaccine, Rotarix, more available for children in", "link": "https://www.thepharmaletter.com/article/humanitarian-mechanism-unlocks-rotarix-for-emergency-use", "pubDate": "2021-03-05 10:26:00"}, {"filename": "novartis-in-deal-to-make-curevac-s-covid-19-vaccine-candidate.json", "title": "Novartis in deal to make CureVac\u00e2\u0080\u0099s COVID-19 vaccine candidate", "description": "Novartis in deal to make CureVac\u00e2\u0080\u0099s COVID-19 vaccine candidate", "link": "https://www.thepharmaletter.com/article/novartis-in-deal-to-make-curevac-s-covid-19-vaccine-candidate", "pubDate": "2021-03-05 10:09:00"}, {"filename": "amgen-replenishes-its-pipeline-with-1-9-billion-acquisition.json", "title": "Amgen replenishes its pipeline with $1.9 billion acquisition", "description": "Amgen replenishes its pipeline with $1.9 billion acquisition", "link": "https://www.thepharmaletter.com/article/amgen-replenishes-its-pipeline-with-1-9-billion-acquisition", "pubDate": "2021-03-04 17:40:00"}, {"filename": "modified-covid-19-vaccines-for-variants-to-be-fast-tracked-say-regulators.json", "title": "Modified COVID-19 vaccines for variants to be fast-tracked, say regulators", "description": "Modified COVID-19 vaccines for variants to be fast-tracked, say regulators", "link": "https://www.thepharmaletter.com/article/modified-covid-19-vaccines-for-variants-to-be-fast-tracked-say-regulators", "pubDate": "2021-03-04 16:26:00"}, {"filename": "ema-starts-rolling-review-of-the-sputnik-v-covid-19-vaccine.json", "title": "EMA starts rolling review of the Sputnik V COVID-19 vaccine", "description": "EMA starts rolling review of the Sputnik V COVID-19 vaccine", "link": "https://www.thepharmaletter.com/article/ema-starts-rolling-review-of-the-sputnik-v-covid-19-vaccine", "pubDate": "2021-03-04 16:02:00"}, {"filename": "fda-accepts-dupixent-sbla-in-children-with-asthma-for-review.json", "title": "FDA accepts Dupixent sBLA in children with asthma for review", "description": "FDA accepts Dupixent sBLA in children with asthma for review", "link": "https://www.thepharmaletter.com/article/fda-accepts-dupixent-sbla-in-children-with-asthma-for-review", "pubDate": "2021-03-04 15:36:00"}, {"filename": "janux-raises-56-million-to-take-tractr-tech-to-the-clinic.json", "title": "Janux raises $56 million to take \u00e2\u0080\u0098TRACTr\u00e2\u0080\u0099 tech to the clinic", "description": "Janux raises $56 million to take \u00e2\u0080\u0098TRACTr\u00e2\u0080\u0099 tech to the clinic", "link": "https://www.thepharmaletter.com/article/janux-raises-56-million-to-take-tractr-tech-to-the-clinic", "pubDate": "2021-03-04 14:09:00"}, {"filename": "still-no-luck-for-gsk-in-fight-against-novel-coronavirus.json", "title": "Still no luck for GSK in fight against novel coronavirus", "description": "GlaxoSmithKline and Vir Biotechnology have stopped enrollment in the Phase III ACTIV trial testing VIR-7831 as a treatment for COVID-19.", "link": "https://www.thepharmaletter.com/article/still-no-luck-for-gsk-in-fight-against-novel-coronavirus", "pubDate": "2021-03-04 13:03:00"}, {"filename": "companies-team-up-on-mrna-vaccines-for-infectious-diseases-to-protect-against-highly-mutagenic-viruses.json", "title": "Companies team up on mRNA vaccines for infectious diseases to protect against highly mutagenic viruses", "description": NaN, "link": "https://www.thepharmaletter.com/article/companies-team-up-on-mrna-vaccines-for-infectious-diseases-to-protect-against-highly-mutagenic-viruses", "pubDate": "2021-03-04 12:48:00"}, {"filename": "first-jak-inhibitor-to-show-hair-regrowth-in-phase-iii-alopecia-trial.json", "title": "First JAK-inhibitor to show hair regrowth in Phase III alopecia trial", "description": "First JAK-inhibitor to show hair regrowth in Phase III alopecia trial", "link": "https://www.thepharmaletter.com/article/first-jak-inhibitor-to-show-hair-regrowth-in-phase-iii-alopecia-trial", "pubDate": "2021-03-04 12:26:00"}, {"filename": "merck-kgaa-keeps-building-with-superb-business-results.json", "title": "Merck KGaA keeps building with \u00e2\u0080\u0098superb business results\u00e2\u0080\u0099", "description": "German science and technology company Merck KGaA has reported impressive sales and earnings figures in its latest quarterly and full-year 2020 financial results", "link": "https://www.thepharmaletter.com/article/merck-kgaa-keeps-building-with-superb-business-results", "pubDate": "2021-03-04 12:20:00"}, {"filename": "novo-nordisk-looks-set-for-leading-position-in-obesity-market-says-analyst.json", "title": "Novo Nordisk looks set for leading position in obesity market, says analyst", "description": "Novo Nordisk looks set for leading position in obesity market, says analyst", "link": "https://www.thepharmaletter.com/article/novo-nordisk-looks-set-for-leading-position-in-obesity-market-says-analyst", "pubDate": "2021-03-04 11:30:00"}, {"filename": "107-million-write-off-follows-failure-of-pah-drug-trevyent.json", "title": "$107 million write off follows failure of PAH drug Trevyent", "description": "A regulatory filing in the USA reveals that United Therapeutics will drop development of Trevyent (treprostinil), an experimental pulmonary arterial hypertensio", "link": "https://www.thepharmaletter.com/article/107-million-write-off-follows-failure-of-pah-drug-trevyent", "pubDate": "2021-03-04 10:40:00"}, {"filename": "boehringer-renews-collaboration-with-autifony.json", "title": "Boehringer renews collaboration with Autifony", "description": "Boehringer renews collaboration with Autifony", "link": "https://www.thepharmaletter.com/article/boehringer-renews-collaboration-with-autifony", "pubDate": "2021-03-04 10:09:00"}, {"filename": "ovid-therapeutics-rockets-on-news-of-856-million-soticlestat-deal.json", "title": "Ovid Therapeutics rockets on news of $856 million soticlestat deal", "description": "Ovid Therapeutics rockets on news of $856 million soticlestat deal", "link": "https://www.thepharmaletter.com/article/ovid-therapeutics-rockets-on-news-of-856-million-soticlestat-deal", "pubDate": "2021-03-03 17:41:00"}, {"filename": "india-s-first-covid-19-vaccine-shows-efficacy-of-81-in-phase-iii-trial.json", "title": "India\u00e2\u0080\u0099s first COVID-19 vaccine shows efficacy of 81% in Phase III trial", "description": "India\u00e2\u0080\u0099s first COVID-19 vaccine shows efficacy of 81% in Phase III trial", "link": "https://www.thepharmaletter.com/article/india-s-first-covid-19-vaccine-shows-efficacy-of-81-in-phase-iii-trial", "pubDate": "2021-03-03 17:21:00"}, {"filename": "157-million-financing-round-a-monumental-moment-for-atai.json", "title": "$157 million financing round a \u00e2\u0080\u0098monumental moment\u00e2\u0080\u0099 for atai", "description": NaN, "link": "https://www.thepharmaletter.com/article/157-million-financing-round-a-monumental-moment-for-atai", "pubDate": "2021-03-03 16:03:00"}, {"filename": "nice-approval-for-olumiant-a-new-class-of-treatment-for-atopic-eczema.json", "title": "NICE approval for Olumiant, a new class of treatment for atopic eczema", "description": "NICE approval for Olumiant, a new class of treatment for atopic eczema", "link": "https://www.thepharmaletter.com/article/nice-approval-for-olumiant-a-new-class-of-treatment-for-atopic-eczema", "pubDate": "2021-03-03 15:53:00"}, {"filename": "patient-group-echoes-bluebird-bio-stance-over-zynteglo-uk-funding-snub.json", "title": "Patient group echoes bluebird bio stance over Zynteglo UK funding snub", "description": "The Thalassaemia International Federation (TIF) has objected to the UK\u00c2\u00b4s National Institute of Health and Care Excellence (NICE) issuing of a negative recommend", "link": "https://www.thepharmaletter.com/article/patient-group-echoes-bluebird-bio-stance-over-zynteglo-uk-funding-snub", "pubDate": "2021-03-03 15:25:00"}, {"filename": "abbvie-picks-up-option-to-acquire-mitokinin-and-its-pd-candidate.json", "title": "AbbVie picks up option to acquire Mitokinin and its PD candidate", "description": "AbbVie picks up option to acquire Mitokinin and its PD candidate", "link": "https://www.thepharmaletter.com/article/abbvie-picks-up-option-to-acquire-mitokinin-and-its-pd-candidate", "pubDate": "2021-03-03 15:10:00"}, {"filename": "phase-ii-failure-prompts-change-of-track-for-luvadaxistat.json", "title": "Phase II failure prompts change of track for luvadaxistat", "description": "San Diego\u00e2\u0080\u0099s Neurocrine Biosciences has been dealt a blow by negative results from the Phase II INTERACT study of schizophrenia candidate luvadaxistat.", "link": "https://www.thepharmaletter.com/article/phase-ii-failure-prompts-change-of-track-for-luvadaxistat", "pubDate": "2021-03-03 13:28:00"}, {"filename": "argobio-launches-with-50-million-euros-aiming-to-create-pioneering-biotech-spinouts.json", "title": "Argobio launches with 50 million euros, aiming to create pioneering biotech spinouts", "description": "Argobio launches with 50 million euros, aiming to create pioneering biotech spinouts", "link": "https://www.thepharmaletter.com/article/argobio-launches-with-50-million-euros-aiming-to-create-pioneering-biotech-spinouts", "pubDate": "2021-03-03 12:38:00"}, {"filename": "merck-co-s-manufacturing-muscle-drafted-in-to-help-make-j-j-s-covid-19-vaccine.json", "title": "Merck & Co\u00e2\u0080\u0099s manufacturing muscle drafted in to help make J&J\u00e2\u0080\u0099s COVID-19 vaccine", "description": NaN, "link": "https://www.thepharmaletter.com/article/merck-co-s-manufacturing-muscle-drafted-in-to-help-make-j-j-s-covid-19-vaccine", "pubDate": "2021-03-03 12:12:00"}, {"filename": "astrazeneca-prevails-in-patent-litigation-on-symbicort.json", "title": "AstraZeneca prevails in patent litigation on Symbicort", "description": "AstraZeneca prevails in patent litigation on Symbicort", "link": "https://www.thepharmaletter.com/article/astrazeneca-prevails-in-patent-litigation-on-symbicort", "pubDate": "2021-03-03 11:49:00"}, {"filename": "jury-still-out-on-inovio-s-hpv-vaccine.json", "title": "Jury still out on Inovio's HPV vaccine", "description": "Despite claiming success in a Phase III trial of HPV candidate VGX-3100, shares in Inovio Pharmaceuticals fell 15% on Tuesday, as investors worried over the str", "link": "https://www.thepharmaletter.com/article/jury-still-out-on-inovio-s-hpv-vaccine", "pubDate": "2021-03-03 11:31:00"}, {"filename": "safer-sleep-drug-could-break-new-ground-in-europe.json", "title": "Safer sleep drug could break new ground in Europe", "description": "Swiss biotech Idorsia has submitted for European approval for daridorexant, an investigational dual orexin receptor antagonist, in the treatment of insomnia.", "link": "https://www.thepharmaletter.com/article/safer-sleep-drug-could-break-new-ground-in-europe", "pubDate": "2021-03-03 10:04:00"}, {"filename": "wuxi-apptec-buys-uk-crdo-firm-for-135-million.json", "title": "WuXi AppTec buys UK CRDO firm for $135 million", "description": "WuXi AppTec buys UK CRDO firm for $135 million", "link": "https://www.thepharmaletter.com/article/wuxi-apptec-buys-uk-crdo-firm-for-135-million", "pubDate": "2021-03-03 10:03:00"}, {"filename": "icer-warns-of-real-loss-for-patients-of-unreasonably-priced-cholesterol-drugs.json", "title": "ICER warns of real loss for patients of unreasonably priced cholesterol drugs", "description": "The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report on new therapies for treating high cholesterol.", "link": "https://www.thepharmaletter.com/article/icer-warns-of-real-loss-for-patients-of-unreasonably-priced-cholesterol-drugs", "pubDate": "2021-03-02 16:46:00"}, {"filename": "astrazeneca-starts-mass-global-rollout-of-covid-19-vaccine-through-covax.json", "title": "AstraZeneca starts mass global rollout of COVID-19 vaccine through COVAX", "description": "AstraZeneca starts mass global rollout of COVID-19 vaccine through COVAX", "link": "https://www.thepharmaletter.com/article/astrazeneca-starts-mass-global-rollout-of-covid-19-vaccine-through-covax", "pubDate": "2021-03-02 16:38:00"}, {"filename": "cosela-now-launched-in-usa-for-people-with-extensive-stage-sclc.json", "title": "Cosela now launched in USA for people with extensive-stage SCLC", "description": "Cosela now launched in USA for people with extensive-stage SCLC", "link": "https://www.thepharmaletter.com/article/cosela-now-launched-in-usa-for-people-with-extensive-stage-sclc", "pubDate": "2021-03-02 16:02:00"}, {"filename": "who-panel-puts-final-nail-in-coffin-of-trump-s-touted-hydroxychloroquine-for-covid-19-prevention.json", "title": "WHO panel puts final nail in coffin of Trump\u00e2\u0080\u0099s touted hydroxychloroquine for COVID-19 prevention", "description": NaN, "link": "https://www.thepharmaletter.com/article/who-panel-puts-final-nail-in-coffin-of-trump-s-touted-hydroxychloroquine-for-covid-19-prevention", "pubDate": "2021-03-02 15:08:00"}, {"filename": "eisai-s-dayvigo-gets-approval-in-hong-kong.json", "title": "Eisai\u00e2\u0080\u0099s Dayvigo gets approval in Hong Kong", "description": "Eisai\u00e2\u0080\u0099s Dayvigo gets approval in Hong Kong", "link": "https://www.thepharmaletter.com/article/eisai-s-dayvigo-gets-approval-in-hong-kong", "pubDate": "2021-03-02 14:04:00"}, {"filename": "astrazeneca-to-market-junshi-s-toripalimab-in-china.json", "title": "AstraZeneca to market Junshi\u00e2\u0080\u0099s toripalimab in China", "description": NaN, "link": "https://www.thepharmaletter.com/article/astrazeneca-to-market-junshi-s-toripalimab-in-china", "pubDate": "2021-03-02 12:56:00"}, {"filename": "merck-co-follows-astrazeneca-in-voluntarily-withdrawing-indication.json", "title": "Merck & Co follows AstraZeneca in voluntarily withdrawing indication", "description": "US pharma giant Merck & Co became the second company in as many weeks to voluntarily withdraw a US indication for one of its drugs.", "link": "https://www.thepharmaletter.com/article/merck-co-follows-astrazeneca-in-voluntarily-withdrawing-indication", "pubDate": "2021-03-02 12:26:00"}, {"filename": "bureaucracy-preventing-more-active-launch-of-drugs-in-russia.json", "title": "Bureaucracy preventing more active launch of drugs in Russia", "description": "Bureaucracy preventing more active launch of drugs in Russia", "link": "https://www.thepharmaletter.com/article/bureaucracy-preventing-more-active-launch-of-drugs-in-russia", "pubDate": "2021-03-02 12:13:00"}, {"filename": "athenex-tanks-as-it-gets-crl-for-its-breast-cancer-combo-therapy.json", "title": "Athenex tanks as it gets CRL for its breast cancer combo therapy", "description": "Athenex tanks as it gets CRL for its breast cancer combo therapy", "link": "https://www.thepharmaletter.com/article/athenex-tanks-as-it-gets-crl-for-its-breast-cancer-combo-therapy", "pubDate": "2021-03-02 11:37:00"}, {"filename": "oncopeptides-gets-fda-accelerated-approval-for-pepaxto.json", "title": "Oncopeptides gets FDA accelerated approval for Pepaxto", "description": "Oncopeptides gets FDA accelerated approval for Pepaxto", "link": "https://www.thepharmaletter.com/article/oncopeptides-gets-fda-accelerated-approval-for-pepaxto", "pubDate": "2021-03-02 10:34:00"}, {"filename": "russia-s-geropharm-plots-leading-role-in-domestic-insulin-market.json", "title": "Russia\u00e2\u0080\u0099s Geropharm plots leading role in domestic insulin market", "description": "Russia\u00e2\u0080\u0099s Geropharm plots leading role in domestic insulin market", "link": "https://www.thepharmaletter.com/article/russia-s-geropharm-plots-leading-role-in-domestic-insulin-market", "pubDate": "2021-03-02 10:05:00"}, {"filename": "indian-government-expedites-approval-process-to-promote-pharma-innovation.json", "title": "Indian government expedites approval process to promote pharma innovation", "description": "Indian government expedites approval process to promote pharma innovationI", "link": "https://www.thepharmaletter.com/article/indian-government-expedites-approval-process-to-promote-pharma-innovation", "pubDate": "2021-03-01 18:08:00"}, {"filename": "february-2021-pharmaceutical-m-a-round-up.json", "title": "February 2021 pharmaceutical M&A round-up", "description": "There were not many acquisitions in the pharmaceutical industry in February, but three of them were in the billion dollar-plus category.", "link": "https://www.thepharmaletter.com/article/february-2021-pharmaceutical-m-a-round-up", "pubDate": "2021-03-01 17:53:00"}, {"filename": "kartesia-acquires-100-stake-in-adl-biopharma.json", "title": "Kartesia acquires 100% stake in ADL Biopharma", "description": "Kartesia acquires 100% stake in ADL Biopharma", "link": "https://www.thepharmaletter.com/article/kartesia-acquires-100-stake-in-adl-biopharma", "pubDate": "2021-03-01 16:59:00"}, {"filename": "time-to-reform-pricing-and-reimbursement-and-procurement-says-medicines-for-europe.json", "title": "Time to reform pricing and reimbursement and procurement, says Medicines for Europe", "description": "A new report from Medicines for Europe has been highlighted by the group as evidence of the need for pricing and reimbursement and procurement reforms to ensure", "link": "https://www.thepharmaletter.com/article/time-to-reform-pricing-and-reimbursement-and-procurement-says-medicines-for-europe", "pubDate": "2021-03-01 16:30:00"}, {"filename": "teon-thera-inks-collaboration-on-first-in-class-cancer-drug.json", "title": "Teon Thera inks collaboration on first-in-class cancer drug", "description": "Teon Thera inks collaboration on first-in-class cancer drug. Adenosine", "link": "https://www.thepharmaletter.com/article/teon-thera-inks-collaboration-on-first-in-class-cancer-drug", "pubDate": "2021-03-01 16:06:00"}, {"filename": "efpia-weighs-in-on-supply-chain-security.json", "title": "EFPIA weighs in on supply chain security", "description": "The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the opportunity to participate in the European Commission\u00e2\u0080\u0099s structure", "link": "https://www.thepharmaletter.com/article/efpia-weighs-in-on-supply-chain-security", "pubDate": "2021-03-01 14:46:00"}, {"filename": "idorsia-files-nda-for-clazosentan-in-japan.json", "title": "Idorsia files NDA for clazosentan in Japan", "description": "Idorsia files NDA for clazosentan in Japan", "link": "https://www.thepharmaletter.com/article/idorsia-files-nda-for-clazosentan-in-japan", "pubDate": "2021-03-01 14:24:00"}, {"filename": "coronavirus-vaccines-shown-to-be-effective-in-real-world-use.json", "title": "Coronavirus vaccines shown to be effective in real-world use", "description": "In the UK, real-world data analyzed by Public Health England (PHE) show a high level of effectiveness for a single dose of Comirnaty, BioNTech and Pfizer\u00e2\u0080\u0099s coro", "link": "https://www.thepharmaletter.com/article/coronavirus-vaccines-shown-to-be-effective-in-real-world-use", "pubDate": "2021-03-01 12:27:00"}, {"filename": "novartis-piqray-approved-for-advanced-breast-cancer-by-hsa.json", "title": "Novartis\u00e2\u0080\u0099 Piqray approved for advanced breast cancer by HSA", "description": "Novartis\u00e2\u0080\u0099 Piqray approved for advanced breast cancer by HSA", "link": "https://www.thepharmaletter.com/article/novartis-piqray-approved-for-advanced-breast-cancer-by-hsa", "pubDate": "2021-03-01 11:58:00"}, {"filename": "germany-s-merck-sees-blockbuster-potential-in-xevinapant.json", "title": "Germany's Merck sees blockbuster potential in xevinapant", "description": "A major global licensing agreement will see Merck KGaA take possession of xevinapant, a first-in-class cancer medicine.", "link": "https://www.thepharmaletter.com/article/germany-s-merck-sees-blockbuster-potential-in-xevinapant", "pubDate": "2021-03-01 10:47:00"}, {"filename": "uk-awards-first-innovation-passport-to-support-development-of-cutting-edge-medicines.json", "title": "UK awards first \u00e2\u0080\u0098Innovation Passport\u00e2\u0080\u0099 to support development of cutting-edge medicines", "description": "UK awards first \u00e2\u0080\u0098Innovation Passport\u00e2\u0080\u0099 to support development of cutting-edge medicines", "link": "https://www.thepharmaletter.com/article/uk-awards-first-innovation-passport-to-support-development-of-cutting-edge-medicines", "pubDate": "2021-03-01 10:36:00"}, {"filename": "fiocruz-and-moh-plan-largest-vaccine-factory-in-latam.json", "title": "Fiocruz and MoH plan largest vaccine factory in LatAm", "description": "Fiocruz and MoH plan largest vaccine factory in LatAm", "link": "https://www.thepharmaletter.com/article/fiocruz-and-moh-plan-largest-vaccine-factory-in-latam", "pubDate": "2021-03-01 10:29:00"}, {"filename": "fda-green-lights-first-treatment-for-molybdenum-cofactor-deficiency-type-a.json", "title": "FDA green lights first treatment for molybdenum cofactor deficiency Type A", "description": NaN, "link": "https://www.thepharmaletter.com/article/fda-green-lights-first-treatment-for-molybdenum-cofactor-deficiency-type-a", "pubDate": "2021-03-01 10:17:00"}, {"filename": "aam-backs-president-biden-s-supply-chain-executive-order.json", "title": "AAM backs President Biden\u00e2\u0080\u0099s Supply Chain Executive Order", "description": "AAM backs President Biden\u00e2\u0080\u0099s Supply Chain Executive Order", "link": "https://www.thepharmaletter.com/article/aam-backs-president-biden-s-supply-chain-executive-order", "pubDate": "2021-03-01 10:16:00"}, {"filename": "first-in-class-biologic-could-change-the-way-asthma-is-treated.json", "title": "First-in-class biologic could change the way asthma is treated", "description": "Full results from a Phase III trial of tezepelumab, a first-in-class biologic developed by Amgen and AstraZeneca, raise hopes for a breakthrough in the treatmen", "link": "https://www.thepharmaletter.com/article/first-in-class-biologic-could-change-the-way-asthma-is-treated", "pubDate": "2021-03-01 09:46:00"}]